Exhibit
10.2


 


CERTAIN
INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE
OR CONFIDENTIAL. IN THIS EXHIBIT, “[ * ]” INDICATES WHERE SUCH INFORMATION HAS BEEN OMITTED.


 


SHARE
PURCHASE AND TRANSFER AGREEMENT


 


THIS
SHARE PURCHASE AND TRANSFER AGREEMENT (the “Agreement”) is made and entered on June 16, 2017 (“Effective
Date”), by and between BioTime, Inc., a California corporation, with offices at 1010 Atlantic Ave., Suite 102, Alameda, CA
94501 (“BioTime”) HBL-Hadasit Bio-Holdings Ltd., an Israeli corporation, having its place of business at Jerusalem
Bio-Park, 5th Floor Hadassah Ein-Kerem Campus, Jerusalem 91120, Israel (“HBL”), and Cell Cure Neurosciences Ltd.,
an Israeli corporation, having its place of business at Hadassah Ein Kerem, JBP Bldg, 5th floor, Hebrew University of Jerusalem,
Ein Kerem, Jerusalem 9574400, Israel (“Cell Cure”).


 


W
I T N E S S E T H:


 


WHEREAS,
HBL holds 96,025 Ordinary Shares, par value NIS 0.01 each, of Cell Cure, constituting as of the date hereof, 21.20% of Cell Cure’s
issued and outstanding share capital (the “Cell Cure Shares”); and


 


WHEREAS,
BioTime wishes to purchase all of the Cell Cure Shares from HBL and HBL desires to sell the Cell Cure Shares to BioTime, in accordance
with the terms and conditions set forth in this Agreement.


 


NOW,
THEREFORE, the parties hereto hereby agree as follows:


 


1.
Sale of the Shares.


 


1.1
Subject to the terms and conditions of this Agreement, and in reliance upon the representations, warranties, covenants and agreements
contained in this Agreement:


 


1.2
HBL shall sell the Cell Cure Shares to BioTime and BioTime shall purchase the Cell Cure Shares from HBL, for an aggregate purchase price
of US $[ * ], which equals a price per Cell Cure Share of US $[ * ] (the “Purchase Price”), to be paid to HBL at the
Closing (as defined below) in the manner set forth herein.


 


1.3
The Purchase Price shall be paid by BioTime to HBL by issuance to HBL of [ * ] shares of BioTime common stock which are listed on the
NYSE MKT (the “Traded Stock”), [ * ].


 


2.
Closing; Delivery.


 


2.1
Closing. Subject to the satisfaction of the conditions set forth in Section 2.2 below, the transactions contemplated by
this Agreement, shall occur through the electronic exchange of documents and signatures on or about 17:00 (Israel time) on the first
business day following the entrance into effect of that certain amendment to the Amended and Restated Research and License Agreement,
entered into by them on October 7, 2010, as amended, executed by Cell Cure and Hadasit Medical Research Services and Development Ltd.
on June 16, 2017 (unless this condition to the consummation of if the transactions contemplated hereby is waived in writing by both HBL
and BioTime), or at such other time as shall be mutually agreed upon in writing by the BioTime and HBL (the “Closing”).


 


2.2
Conditions to Closing. The obligations of the parties to consummate the transactions contemplated by this Agreement at the Closing
are subject to the fulfillment, on or before the Closing, of each of the following conditions, unless otherwise waived in writing by
either HBL or BioTime, as applicable:


 


2.2.1
Representations and Warranties. The representations and warranties of BioTime contained in Section 3 and the representations
and warranties of HBL contained in Section 4 shall be true and correct in all respects as of the Closing.


 




    	 



     


    

 


2.2.2
Performance. Each of BioTime and HBL shall have performed and complied with all covenants, agreements, obligations and conditions
contained in this Agreement that are required to be performed or complied with by such party on or before the Closing.


 


2.2.3
Consents. All authorizations, approvals or permits, if any, that are required in connection with the lawful sale and transfer
of the Purchased Shares and the issuance of the Traded Stock to HBL pursuant to this Agreement shall be obtained by BioTime and HBL,
as applicable, and effective as of the Closing.


 


2.2.4
Deliveries and Transactions. At the Closing, the following transactions shall occur (the “Transactions”), which
Transactions shall be deemed to take place simultaneously and no Transaction shall be deemed to have been completed or any document described
in this Section 2.2.4 delivered until all such Transactions have been completed and all required documents delivered:


 


2.2.4.1
Issuance by BioTime to HBL of the Traded Stock in accordance with Section 1.3 above. In the event that HBL delivers to BioTime
a Trustee Tax Certificate (as defined below) at or prior to Closing, then upon receipt thereof, BioTime shall deposit, or cause to be
deposited, with a trustee appointed by HBL (the “Trustee”), such number of Traded Stock in accordance of Sections
1.2 and 1.3 (the “Closing Payment Fund”). For the purpose of this Agreement, “Trustee Tax Certificate”
means a certificate or ruling of exemption of withholding tax or arrangement to pay, or a deferral of payment of any taxes required to
be so paid by HBL, issued by relevant tax authority whereby all responsibility for payment of any taxes required to be so paid by HBL
shall fall of the Trustee and exempting BioTime from the duty to withhold any tax, in a form and substance acceptable to BioTime.


 


2.2.4.2
HBL shall have delivered to BioTime (i) a Trustee Tax Certificate, or (ii) HBL Tax Certificate (as defined below) exempting BioTime from
the duty to withhold any tax on the Closing date, or (iii) an amount in cash equal to the amount required to be withheld by BioTime pursuant
to Section 9.6 below.


 


2.2.4.3
The execution and delivery by HBL and BioTime of a share transfer deed, substantially in the form attached hereto as Schedule A.


 


2.2.4.4
HBL shall provide Cell Cure with letters of resignation of both of the directors appointed to the Board of Directors of Cell Cure by
HBL, substantially in the form attached hereto as Schedule B.


 


2.2.4.5
The execution and delivery by HBL and BioTime of the Debt Purchase Agreement, substantially in the form attached hereto as Schedule
C, and consummation of the Closing thereunder (as such term is defined therein).


 


2.2.4.6
The Board of Directors of Cell Cure shall have approved the Transaction (the “Board Consent”) and Cell Cure shall
have delivered to HBL and BioTime a true and correct copy of such Board Consent.


 


2.2.4.7
All Qualified Shareholders of Cell Cure (as such term is defined in Cell Cure’s Third Amended and Restated Articles of Association,
as amended on March 12, 2012, February 3, 2014 and on December 20, 2016 (the “Cell Cure’s Articles”) shall have
submitted a duly executed waiver of rights issued to them in accordance with Cell Cure’s Articles.


 


2.2.4.8
The Registration Statement (as defined below) for the Traded Stock filed in accordance with Section 8.1, being declared effective
by Securities and Exchange Commission (the “SEC”).


 


3.
Representations and Warranties of BioTime. BioTime hereby makes the following representations and warranties to HBL:


 


3.1
BioTime has the requisite power and authority to enter into this Agreement and to consummate the transactions contemplated hereby and
otherwise to carry out its obligations hereunder. This Agreement, and any ancillary document hereto, when executed and delivered by BioTime,
shall be duly and validly authorized, executed and delivered by BioTime and constitute the valid and legally binding obligations of BioTime,
legally enforceable against it in accordance with its terms, subject, however, to applicable bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and similar laws of general applicability relating to or affecting creditor’s rights and to general
equitable principles.


 




    	-2-



    	 



    

 


3.2
As the majority shareholder of Cell Cure, it is familiar with the condition and operations of Cell Cure and in addition, has had the
opportunity to ask questions of and receive answers from and/or obtain additional information from, the management of Cell Cure concerning
the financial and other affairs of Cell Cure.


 


3.3
BioTime has obtained the requisite consents, approvals and/or agreement of any individual or entity as required to be obtained by BioTime
to execute and perform this Agreement or any agreements, instruments or other obligations entered into in connection with this Agreement,
and the transaction contemplated hereby and thereby, including the issuance of the Traded Stock to HBL pursuant to Section 1.3.


 


3.4
The Traded Stock to be issued pursuant to this Agreement will not be issued in violation of any preemptive rights, right of first refusal
and\or any other rights of the current or past shareholders of BioTime, or any agreement to which BioTime was or is a party or bound.
When issued and delivered in accordance with this Agreement, the Traded Stock shall be (a) duly and validly authorized, issued and outstanding,
in compliance with all applicable federal or state securities laws, fully paid and non-assessable, and issued in compliance with all
applicable federal or state securities laws, (b) listed for trading on the NYSE MKT and will be able to be sold under the Registration
Statement assuming compliance the prospectus delivery requirements, and (c) free and clear of any liens, claims, charges, rights, pledges,
security interests, mortgages, options, title defects or other encumbrances, restrictions or limitations of any nature whatsoever, or
other security interest of any kind or character or any right of any third party.


 


3.5
All registration statements, certifications, forms, reports and other documents (the “Company Reports”) filed by BioTime
with the SEC : (i) complied in all material respects with the applicable requirements of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), Securities Act of 1933, as amended (“Securities Act”), and the Sarbanes-Oxley
Act of 2002 (the “Sarbanes-Oxley Act”), as the case may be, and the rules and regulations thereunder applicable to
such Company Reports at the time such Company Report was filed or submitted with the SEC; and (ii) did not contain any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. Since January 1, 2015, BioTime has been in compliance in
all material respects with (i) the applicable provisions of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act (and (ii)
the applicable listing and corporate governance rules and regulations of NYSE MKT and other requirements of the California Corporations
Code.


 


3.6
The consolidated financial statements (including any related notes) contained in the Company Reports: (i) complied as to form in all
material respects with any applicable law and the published rules and regulations of the SEC applicable thereto; (ii) were prepared in
accordance with US GAAP applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such
financial statements and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring
year-end adjustments that will not, individually or in the aggregate, be material in amount), and (iii) fairly presented, in all material
respects, the consolidated financial position of BioTime as of the respective dates thereof and the results of operations and cash flows
of BioTime for the periods covered thereby.


 


4.
Representations and Warranties of HBL. HBL hereby makes the following representations and warranties to BioTime:


 


4.1
HBL owns the Cell Cure Shares free and clear of all any and all liens, claims, encumbrances, preemptive rights, right of first refusal
and adverse interests of any kind, except as set forth in the Cell Cure’s Articles and Cell Cure’s shareholder agreement.


 


4.2
HBL has the requisite power and authority to enter into this Agreement and to consummate the transactions contemplated hereby and otherwise
to carry out its obligations hereunder. This Agreement, and any ancillary document hereto, when executed and delivered by HBL, shall
be duly and validly authorized, executed and delivered by HBL and constitute the valid and legally binding obligations of HBL, legally
enforceable against it in accordance with its terms, subject, however, to applicable bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability relating to or affecting creditor’s rights and to general equitable principles.


 




    	-3-



    	 



    

 


4.3
HBL has obtained the requisite consents, approvals and/or agreement of any individual or entity as required to be obtained by HBL in
connection with the execution and performance by HBL of this Agreement or the execution and performance by HBL of any agreements, instruments
or other obligations entered into in connection with this Agreement, including, but not limited to, any authorizations required from
the Israeli Securities Authority, if any.


 


4.4
Effective as of the Closing date (and subject to the consummation thereof), HBL shall be deemed as having irrevocably waived all of the
rights specifically afforded to it under the Amended and Restated Shareholders Agreement by and between Cell Cure’s shareholders,
dated October 7, 2010, as amended, and the same shall not be applicable, even if HBL again becomes a shareholder of Cell Cure at any
time thereafter.


 


5.
Publication.


 


The
parties have agreed this Agreement and the transaction contemplated hereunder are confidential and shall not be disclosed by either party.
Accordingly, neither party shall issue any press release, statement or other disclosure regarding this Agreement other than as set forth
in Schedule D attached hereto or such other disclosure as shall be agreed upon the parties. The above limitation shall
not apply to the extent that such disclosure is required under applicable securities law or regulation (including the Exchange Act) or
the Tel-Aviv Stock Exchange rules.


 


6.
Cell Cure’s Confirmation.


 


Cell
Cure hereby consents to the transfer of the Purchased Shares under this Agreement and certifies that the transactions contemplated by
this Agreement, including the transfer of the Purchased Shares, were duly authorized and approved by its Board of Directors and are in
compliance with Cell Cure’s Articles and organizational documents and shareholder agreement.


 


7.
Termination.


 


This
Agreement may be terminated at any time prior to the Closing by each of HBL or BioTime by delivering the other parties a written notice,
if the Closing does not occur within ninety (90) days of the Effective Date, provided such delay in Closing is not caused by the terminating
party.


 


8.
Registration Rights.


 


8.1
Within fifteen (15) days from the Effective Date, unless otherwise agreed upon in writing by HBL and BioTime), BioTime shall file with
the SEC a registration statement on a Form S-3 to register for resale the Traded Stock with the SEC (“Registration Statement”)
and shall provide HBL with a copy of the Registration Statement within two (2) business day from the date of filing the Registration
Statement with the SEC. Prior to filing such Registration Statement, BioTime shall give HBL a reasonable opportunity to review and comment
on the Registration Statement, and BioTime agrees to include all reasonable comments provided by HBL or its legal counsel. BioTime’s
obligation to file the Registration Statement shall be dependent upon HBL’s providing the information necessary for BioTime to
include in the Registration Statement relating to HBL’s capacity as a selling stockholder thereunder.


 


8.2
BioTime shall use its commercially reasonable efforts to cause such Registration Statement to become effective and keep such registration
statement effective until all the securities covered by such Registration Statement may be freely traded by HBL without volume restrictions
under Rule 144 promulgated under the Securities Act (“Rule 144”). BioTime shall use its commercially reasonable efforts
to cause all securities covered by such Registration Statement to be listed on the NYSE MKT.


 


8.3
All expenses incurred in connection with the Registration Statement, including all registration, filing, and qualification fees; printers’
and accounting fees; fees and disbursements of counsel for BioTime, shall be borne by the [ * ] shall be responsible for the fees and
expenses of its own legal counsel in connection with the Registration Statement.


 




    	-4-



    	 



    

 


8.4
With a view to making available to the HBL the benefits of Rule 144, BioTime shall:


 


8.4.1
make and keep available adequate current public information, as those terms are understood and defined in Rule 144, at all times after
the effective date of the Registration Statement;


 


8.4.2
use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of BioTime under
the Securities Act and the Exchange Act; and


 


8.4.3
furnish to HBL, so long as HBL owns any Traded Stock, forthwith upon request (i) to the extent accurate, a written statement by BioTime
that it has complied with the reporting requirements of Rule 144, the Securities Act, and the Exchange Act, or that it qualifies as a
registrant whose securities may be resold pursuant to Form S-3; and (ii) such other information as may be reasonably requested in availing
HBL of any rule or regulation of the SEC that permits the selling of any such securities without registration or pursuant to Form S-3.


 


8.5
Indemnification.


 


8.5.1
To the extent permitted by law, BioTime will indemnify and hold harmless HBL, and the officers, directors and shareholders of HBL, legal
counsel and accountants for HBL; any underwriter (as defined in the Securities Act) for HBL; and each Person, if any, who controls HBL
or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages (as defined below), and BioTime will
pay to HBL, underwriter, controlling individual, corporation, partnership, trust, limited liability company, association or other entity
(collectively, “Person”), or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection
with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however,
that the indemnity agreement contained in this subsection shall not apply to amounts paid in settlement of any such claim or proceeding
if such settlement is effected without the consent of BioTime, at its discretion, nor shall BioTime be liable for any Damages to the
extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information
furnished by or on behalf of HBL, underwriter, controlling Person, or other aforementioned Person. “Damages” means
any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange
Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of
or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of
BioTime or HBL, as applicable, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements
thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the
statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates
(as defined in Cell Cure’s Articles)) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation
promulgated under the Securities Act, the Exchange Act, or any state securities law.


 


8.5.2
To the extent permitted by law, HBL will indemnify and hold harmless BioTime and each of its directors, each of its officers who has
signed the registration statement, each Person (if any), who controls BioTime within the meaning of the Securities Act, legal counsel
and accountants for BioTime, any underwriter (as defined in the Securities Act), and any controlling Person of any such underwriter,
against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance
upon and in conformity with written information furnished by or on behalf of HBL; and HBL will pay to BioTime and each other aforementioned
Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding
from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this subsection
shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of HBL,
at its discretion; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution
under this subsection (ii) or subsection (iv) below exceed the proceeds from the offering received HBL (net of any selling expenses paid
by HBL), except in the case of fraud or willful misconduct by HBL.


 




    	-5-



    	 



    

 


8.5.3
Promptly after receipt by an indemnified party under this Section 8.5 of notice of the commencement of any action (including any
governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party under this Section 8.5, give the indemnifying party notice of the commencement
thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires,
participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel
mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that
may be represented without conflict by one counsel) shall have the right to retain one separate counsel, at its expense unless representation
of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential conflict
of interest between such indemnified party and any other party represented by such counsel in such action. The failure to give notice
to the indemnifying party will not relieve it of any liability that it may have to any indemnified party except if such failure shall
have materially prejudiced the indemnifying party.


 


8.5.4
To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 8.5 but it is judicially
determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the
denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section
8.5 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party
hereto for which indemnification is provided under this Section 8.5, then, and in each such case, such parties will contribute
to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such
proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection
with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect
any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined
by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged
omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’
relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,
that, in any such case (x) HBL shall not be required to contribute any amount in excess of the public offering price of all such Traded
Stock offered and sold by HBL pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent
misrepresentation; and provided further that in no event shall HBL’s liability pursuant to this subsection (iv), when combined
with the amounts paid or payable by HBL pursuant to subsection (ii), exceed the proceeds from the offering received by HBL (net of any
selling expenses paid by HBL), except in the case of willful misconduct or fraud by HBL.


 


9.
Miscellaneous.


 


9.1
Entire Agreement; Amendment. This Agreement and the schedules and exhibits hereto, constitute the full and entire understanding
and agreement between the parties with regard to the subject hereof, and no party shall be liable or bound to any other party in an manner
by any warranties, representations or covenants except as specifically set forth herein or therein. Neither this Agreement nor any term
hereof may be amended, waived or discharged other than by a written instrument signed by all the parties hereto.


 


9.2
Notices. All notices and other communications given or made pursuant hereto shall be in writing, in English and shall be deemed
effectively given: (i) upon delivery to the party if delivered personally or via courier; (ii) when sent by confirmed electronic mail
or facsimile if sent during normal business hours of the recipient; if not, then on the next business day; or (iii) on the date set forth
on the return receipt, if sent by registered or certified mail, return receipt requested, postage prepaid. All notices and communications
shall be sent to the parties at the addresses set forth on the signature page below (or at such other addresses as shall be specified
by notice given in accordance with this Section 9.2).


 


9.3
Assignment. Neither party may assign, convey or transfer any of its rights or obligations under this Agreement; provided, that
HBL may assign it rights hereunder to any of its Affiliates (as such term is defined in Cell Cure’s Articles).


 




    	-6-



    	 



    

 


9.4
Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party upon any breach or default
under this Agreement shall be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit,
consent, or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on
the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent
specifically set forth in such writing.


 


9.5
Severability. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to
be illegal, unenforceable or void, this Agreement shall continue in full force and effect without said provision; provided, however,
that in such event this Agreement shall be interpreted so as to give effect, to the greatest extent consistent with and permitted by
applicable law, to the meaning and intention of the excluded provision as determined by such court of competent jurisdiction.


 


9.6
Expenses; taxes. Each party shall bear all taxes incurred by it in connection with the Transactions and for which such party is
statutorily liable. However, in the event that BioTime is required to withhold income taxes at source with respect to the transfer of
the Traded Stock pursuant to Section 2.2.4.2 above, BioTime shall have the right to withhold such amounts as required under applicable
tax law at the applicable rate for such withholding in accordance with applicable law or a HBL Tax Certificate providing for a reduced
rate. “HBL Tax Certificate” means a certification or ruling of exemption of withholding tax and/or proof of payment,
or arrangement to pay, or a deferral of payment of any taxes required to be so paid by HBL, issued by relevant tax authority, in a form
and substance acceptable to BioTime.


 


9.7
Representation; waiver of conflict of interest. Each party hereto acknowledges that it has had the opportunity to obtain independent
legal and tax advice prior to executing this Agreement and fully understands all provisions of this Agreement. HBL and BioTime recognize
and acknowledge that counsel to BioTime also represents Cell Cure in connection with various legal matters and each of BioTime and HBL
waive any conflict of interest or other allegations in this regard.


 


9.8
Governing Law and Jurisdiction. This Agreement shall be governed in all respects by the laws of the State of Israel. Any proceeding
regarding a dispute arising under or in relation to this Agreement shall be resolved solely and exclusively in the competent court located
(i) in the city of Tel Aviv, Israel, if such proceeding is initiated by BioTime, and (ii) in the city of New York, New York, if such
proceeding is initiated by HBL, and each of the parties hereto hereby irrevocably submit to the exclusive jurisdiction of such venue.


 


9.9
Counterparts. This Agreement may be executed in any number of counterparts and the executed signature pages sent to the other
parties by facsimile transmission or PDF shall be binding as evidence of such party’s agreement hereto and acceptance hereof.


 


[SIGNATURE
PAGE FOLLOWS]


 




    	-7-



    	 



    

 


IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.


 


	/s/
    Aditya P. Mohanty	 	/s/
    Baruch Halpert
	BioTime
    Inc.	 	HBL-Hadasit
    Bio-Holdings Ltd.


 


	Name:	Aditya
    O. Mohanty	 	Name:	Baruch
    Halpert
	Title:	Co-CEO	 	Title:	Chairman


 


	1010
    Atlantic Ave., Suite 102	Jerusalem
    Bio-Park, 5th Floor
	Alameda,
    CA 94501	Hadassah
    Ein-Kerem Campus,
	USA	Jerusalem
    91120
	 	Israel


 


	Facsimile:	 	 	 
	E-mail:	 	 	Facsimile:	 	 
	Attn:	 	 	E-mail:	 	 
	 	Attn:	 	 


 


	 	/s/
    Rami Skaliter	 
	 	Cell
    Cure Neurosciences Ltd.	 
	 	 	 
	 	Name:	Rami
    Skaliter	 
	 	Title:	Chief
    Scientific Officer	 


 


	 	P.O.
    Box 12000
	 	JBP
    Bldg, 5th floor
	 	Hadassah
    Ein Kerem
	 	Hebrew
    University of Jerusalem,
	 	Ein
    Kerem, Jerusalem 91120
	 	Israel
	 	Facsimile:
    02-642-9856
	 	E-mail:	       	 
	 	Attn:
    CEO


 




    	-8-



    	 



    

 


SCHEDULE
A


 


Share
Transfer Deed


 


Schedule
A


 


Share
Transfer Deed


 


The
undersigned, HBL-Hadasit Bio-Holdings Ltd. (the “Transferor”), hereby transfers to BioTime, Inc. (the “Transferee”),
for consideration received, the sufficiency of which is hereby acknowledged, all of the rights, title and interests in 96,025 Ordinary
Shares, par value NIS 0.01 each of Cell Cure Neurosciences ltd. (“Cell Cure”) to hold unto the Transferee and the
successors and assigns of the Transferee, all upon the terms and conditions pursuant to the Articles of Association of Cell Cure, as
shall be in effect from time to time., and the Transferree does hereby agree to accept and hold such shares subject to the above terms
and conditions.


 


	BioTime,
    Inc.	 	HBL-Hadasit
    Bio-Holdings Ltd.	 
	 	 	 	 
	 	 	 	 
	Name:
    Aditya Mohanty	 	Name:
    Baruch Halpert	 
	Title:
    Co-Chief Executive Officer	 	Title:
    Chairman	 


 


	 	 	 	 
	 	 	Name:
    Yoram Azulai	 
	 	 	Title:
    CFO, acting CEO	 
	 	 	 	 
	 	 	 	 
	Witness
    to the signature	 	Witness
    to the signature	 
	of
    the Transferee	 	of
    the Transferor	 


 




    	-9-



    	 



    

 


SCHEDULE
B


 


Letters
of Resignation


 


SCHEDULE
B


 


FORM
OF LETTER OF RESIGNATION


 


	To:	Cell
    Cure Neurosciences Ltd. (the “Company”)
	 	 
	Re:	Resignation
    from the Board of Directors


 


I,
undersigned, hereby resign from the Board of Directors of the Company subject to and effective as of immediately following the Closing
of the Share Purchase and Transfer Agreement by and among BioTime, Inc., HBL-Hadasit Bio-Holdings Ltd., and the Company, dated June 16,
2017 (the “SPA”). Capitalized terms used herein and not defined herin shall have the meaning ascribed to them in the
SPA.


 


	 	 
	Michel
    Habib	 


 




    	-10-



    	 



    

 


SCHEDULE
B


 


FORM
OF LETTER OF RESIGNATION


 


	To:	Cell
    Cure Neurosciences Ltd. (the “Company”)
	 	 
	Re:	Resignation
    from the Board of Directors


 


I,
undersigned, hereby resign from the Board of Directors of the Company subject to and effective as of immediately following the Closing
of the Share Purchase and Transfer Agreement by and among BioTime, Inc., HBL-Hadasit Bio-Holdings Ltd., and the Company, dated June 16,
2017 (the “SPA”). Capitalized terms used herein and not defined herin shall have the meaning ascribed to them in the
SPA.


 


	 	 
	Baruch
    Halpert	 


 




    	-11-



    	 



    

 


SCHEDULE
C


 


Debt
Purchase Agreement


 


DEBT
AND NOTE PURCHASE AGREEMENT


 


THIS
DEBT AND NOTE PURCHASE AGREEMENT (the “Agreement”) is made and entered on June 16 2017 (“Effective Date”), by
and between BioTime Inc., a California corporation, with offices at 1010 Atlantic Ave., Suite 102, Alameda, CA 94501 (“BioTime”)
and HBL-Hadasit Bio-Holdings Ltd., an Israeli corporation, having its place of business at Jerusalem Bio-Park, 5th Floor Hadassah Ein-Kerem
Campus, Jerusalem 91120, Israel (“HBL”).


 


W
I T N E S S E T H:


 


WHEREAS,
HBL remitted loans to Cell Cure Neurosciences Ltd. (“Cell Cure”), in the aggregate principal amount of US [ * ] under certain
Subscription Offers and Loan Agreements and the promissory notes issued thereunder (collectively, the “Loan Documents”),
all as detailed in Exhibit A attached hereto (collectively with accrued interest thereof as of the date hereof, in the amount
of US [ * ], the “Cell Cure Debt”); and


 


WHEREAS,
BioTime wishes to purchase the Cell Cure Debt from HBL and to assume all of HBL’s rights and obligations under the Loan Documents
and HBL desires to sell the Cell Cure Debt to BioTime and to assign the Loan Documents to BioTime, all in accordance with the terms and
conditions set forth in this Agreement; and


 


NOW,
THEREFORE, the parties hereto hereby agree as follows:


 


1.
Sale of the Debt; Issuance of Warrant; Participation Rights.


 


1.1
Subject to the terms and conditions of this Agreement, and in reliance upon the representations, warranties, covenants and agreements
contained in this Agreement:


 


1.2
HBL shall sell the Cell Cure Debt to BioTime and BioTime shall purchase the Cell Cure Debt from HBL, for an aggregate purchase price
of [ * ] (the “Purchase Price”), to be paid to HBL at the Closing (as defined below) in the manner set forth herein.


 


1.3
The Purchase Price shall be paid by BioTime to HBL by issuance to HBL of [ * ] shares of BioTime common stock which are listed on the
NYSE MKT (the “Traded Stock”), [ * ].


 


1.4
HBL and BioTime hereby undertake to vote all of their shares in Cell Cure in favor of this Agreement, the SPA (as defined below) and
the transactions contemplated hereunder and thereunder, subject to the terms and conditions set forth herein and therein. HBL and BioTime
further irrevocably and unconditionally undertake to take all further acts and to execute all documents and instruments (including all
corporate resolutions, share transfer deeds and any other documents and instruments), as required to consummate the transaction contemplated
hereunder and thereunder, all in accordance with and subject to the terms and conditions set forth herein and therein.


 


1.5
In the event that during the period commencing on the Effective Date and ending on the earlier of the Closing and the date of termination
of this Agreement pursuant to Section 6 (the “Effective Period”), Cell Cure consummates any Financing Transaction
(as defined below), HBL hereby agrees and confirms that it shall not participate in such Financing Transaction; provided, however that
if the Closing does not occur for any reason whatsoever, HBL shall be entitled to participate in each Financing Transaction consummated
during the Effective Period, [ * ] Cell Cure’s Third Amended and Restated Articles of Association, as amended on March 12, 2012,
February 3, 2014 and on December 20, 2016 (“Cell Cure’s Articles”) [ * ], in accordance with and subject to
the provisions of this Section 1.5. The term “Financing Transaction” means any financing transaction in which
Cell Cure raises funds through the issuance of shares and\or other securities, including, without limitation, any loan agreements, promissory
notes or other commitments which by their terms are exchangeable, exercisable or convertible for or into share capital of Cell Cure;
the term “Internal Financing Transaction” means any Financing Transaction between Cell Cure and its existing shareholders,
including under Section 9 (‘Further Funding’) of the Amended and Restated Shareholders Agreement by and between Cell
Cure’s shareholders, dated October 7, 2010, as amended (the “Shareholders Agreement”); the term “External
Financing Transaction” means any Financing Transaction which does not constitute an Internal Financing Transaction; and the
term “Financing Transaction Agreements” means the applicable agreements governing the Financing Transaction and all
ancillary agreements and documents thereto.


 




    	-12-



    	 



    

 


1.5.1
In the event Cell Cure consummates an Internal Financing Transaction during the Effective Period, HBL may elect to participate in any
Internal Financing Transaction(s) [ * ] by delivering BioTime and Cell Cure a written notice during the initial [ * ] days following
the Effective Period (an “Internal Participation Notice”), in such amount as shall be described in the Internal Participation
Notice (the “HBL Internal Participation Amount”). If HBL provides BioTime and Cell Cure with an Internal Participation
Notice within the above-mentioned period, then within [ * ] business days after receipt of the Internal Participation Notice, HBL will
remit the HBL Internal Participation Amount directly to BioTime and BioTime, unconditionally, will assign its rights under the applicable
Financing Transaction Agreements relating to the HBL Internal Participation Amount (including any Cell Cure securities) and take all
further acts and execute all documents and instruments as required, such that HBL shall become a party to such agreements, in accordance
with Section 1.5.3.


 


1.5.2
In the event Cell Cure consummates an External Financing Transaction during the Effective Period, then HBL may elect to participate in
such External Financing Transaction(s) [ * ] by delivering to BioTime and Cell Cure a written notice during the initial [ * ] days following
the Effective Period (an “External Participation Notice”), in such amount as shall be described in the External Participation
Notice (the “HBL External Participation Amount”). If HBL provides BioTime and Cell Cure an External Participation
Notice within the above-mentioned period, then within five (5) business days after receipt of the External Participation Notice, HBL
will remit the HBL Internal Participation Amount to Cell Cure and HBL shall become a party to the applicable Financing Transaction Agreements,
in accordance with Section 1.5.3.


 


1.5.3
BioTime shall notify HBL of any Financing Transaction consummated during the Effective Period by providing HBL a written notice by no
later than [ * ] days following the closing thereof and shall provide HBL with a true and complete copy of all Financing Transaction
Agreements. BioTime shall ensure that Cell Cure shall take all acts as required to enable the participation of HBL pursuant to this Section
1.5 in any Financing Transaction consummated during the Effective Period, including the reservation of such amount out of the aggregate
investment amount equal to [ * ]. Upon participation pursuant to Section 1.5.1 or 1.5.2 above, HBL shall be entitled to
[ * ] in such Financing Transaction (the “Investors”), on a pari-passu basis, as if the HBL Internal Participation
Amount or HBL External Participation Amount, as applicable, was invested by HBL under the Financing Transaction Agreements at the closing
thereof, all in accordance with the terms and conditions set forth therein. [ * ] shall ensure that [ * ] takes all actions reasonably
necessary to ensure that HBL shall be added as a party to the Financing Transaction Agreements for purpose of providing it with the rights
and benefits of the Investors on a proportionate basis, including any shareholder rights, the right to rely on representations and warranties
provided thereunder and to be indemnified in connection therewith.


 


1.5.4
Failure by HBL to provide an Internal Participation Notice or External Participation Notice, as applicable, with respect to a specific
Financing Transaction consummated during the Effective Period, shall be deemed a wavier by HBL of its participation right under this
Section 1.5 with respect to such Financing Transaction, all subject to the compliance of Cell Cure and BioTime with their respective
obligations under this Section 1.5.


 


1.6
In the event that Cell Cure consummates a Financing Transaction through the issuance of shares during the five (5) year period following
Closing (the “Qualifying Period”), then upon the closing of such Financing Transaction, BioTime shall ensure that
Cell Cure shall issue to HBL a warrant, substantially in the form attached hereto as Exhibit C (the “Investment
Warrant”), to purchase shares of the same type and class as issued in such Financing Transaction, in an amount equal to 5%
of the aggregate amount of Cell Cure’s securities issued as part of such Financing Transaction at an exercise price equal to the
[ * ]. Each Investment Warrant shall be exercisable during a period of five (5) years commencing on the Closing, subject to the terms
and conditions set forth therein. Cell Cure shall notify HBL of such Financing Transaction by providing HBL a written notice by no later
than five (5) days prior to the closing thereof. Is it hereby agreed and acknowledged that in the event that HBL is entitled to an Investment
Warrant pursuant to this Section 1.6 and Cell Cure fails to issue HBL such Investment Warrant, BioTime shall grant HBL an option
to purchase shares of Cell Cure held by it, of the same type and class as issued in such Financing Transaction, in an amount and at an
exercise price equal to [ * ] (a “BioTime Call Option”). BioTime undertakes to reserve that number of shares of Cell
Cure held by it, as may be required from time to time to allow for the issuance and exercise of BioTime Call Option(s), free and clear
of all pre-emptive rights, liens, pledges, security interests, charges and encumbrances. In the event of an exercise of a BioTime Call
Option, HBL shall be entitled to deduct and withhold from the aggregate exercise price, upon exercise thereof, otherwise payable to BioTime
under the terms thereof, such amounts as HBL is required to deduct and withhold with respect to the making of such payment under applicable
tax law at the applicable rate for such withholding, unless BioTime provides HBL a valid tax certificate issued by the Israeli tax authority,
in a form and substance acceptable to HBL, stating that no withholding, or reduced withholding, of tax is required in connection with
the payment of the exercise price from HBL to BioTime, in which case the taxes shall not be withheld, or shall be withheld at the applicable
reduced rate.


 




    	-13-



    	 



    

 


1.7
For as long as the Debt Warrant (defined below) remains exercisable, and thereafter for as long as HBL holds any shares of Cell Cure,
BioTime shall ensure that HBL shall be entitled to appoint, replace and dismiss, on its behalf, one (1) observer (the “HBL Observer”)
to Cell Cure’s Board of Directors (the “Board”) who shall be invited to and shall have the right to attend all
meetings (including meetings held by any means of communication) of the Board in a non-voting capacity and to receive any and all notices,
information, materials and proposed resolutions (including, without limitation, any proposed resolutions for adoption in writing) delivered
to the members of the Board concurrently with the delivery thereof to the members of the Board; provided, however, that
the HBL Observer may be excluded from any Board meeting or portion thereof and need not be provided such materials if the Board reasonably
determines in good faith that such exclusion of the HBL Observer’s attendance at such meeting or access to such information is
necessary in order to preserve an attorney-client privilege or to avoid a conflict of interest between Cell Cure and HBL.


 


1.8
BioTime and HBL each ensure that any and all outstanding convertible loans remitted to Cell Cure by them prior to the Closing, including
the Cell Cure Debt and all convertible loans remitted to Cell Cure by BioTime, and the promissory notes issued thereunder (collectively,
“Cell Cure’s Convertible Loans”), shall be converted into non-convertible loans and the governing documents
with respect thereof, including the Loan Documents (collectively, “Cell Cure’s Loan Documents”),shall be amended,
such that immediately prior to the Closing, Cell Cure shall have no convertible loans and\or other securities, promissory notes or other
securities or commitments which by their terms are exchangeable, exercisable or convertible for or into share capital of Cell Cure (“Convertible
Securities”), excluding (a) the warrant issued by Cell Cure to Hadasit Research Services and Development Ltd. dated October
7, 2010; (b) the warrant issued to [ * ] dated August 1, 2016; (c) the loan remitted by [ * ] under the Subscription Offer dated May
8, 2014 and Subscription Offer dated November 10, 2015, in the aggregate principal amount of US[ * ] (the “[ * ] Loans”);
and (d) any outstanding options that have been or may be issued under Cell Cure’s option plan and any shares reserved or to be
reserved for issuance thereunder.


 


1.9
During the Qualifying Period, BioTime shall ensure that Cell Cure shall not consummate a Financing Transaction other than through the
issuance of shares and that neither BioTime nor any other third party will remit convertible loans and\or funds to Cell Cure in consideration
of the issuance of Convertible Securities, unless BioTime obtains HBL’s prior written consent to such remittance and issuance.


 


2.
Closing; Delivery.


 


2.1
Closing. The transactions contemplated by this Agreement shall occur through the electronic exchange of documents on the date
of Closing of the SPA (as such term is defined therein), subject to the satisfaction of the conditions set forth in Section 2.2
below (the “Closing”).


 


2.2
Conditions to Closing. The obligations of the parties to consummate the transactions contemplated by this Agreement at the Closing
are subject to the fulfillment, on or before the Closing, of each of the following conditions, unless otherwise waived in writing by
either HBL or BioTime, as applicable:


 


2.2.1
Representations and Warranties. The representations and warranties of BioTime contained in Section 3 and the representations
and warranties of HBL contained in Section 4 shall be true and correct in all respects as of the Closing.


 




    	-14-



    	 



    

 


2.2.2
Performance. Each of BioTime and HBL shall have performed and complied with all covenants, agreements, obligations and conditions
contained in this Agreement that are required to be performed or complied with by such party on or before the Closing.


 


2.2.3
Consents. All authorizations, approvals or permits, if any, that are required in connection with the lawful sale and transfer
of the Cell Cure Debt and the issuance of the Traded Stock to HBL pursuant to this Agreement shall be obtained by BioTime and HBL, as
applicable, and effective as of the Closing.


 


2.2.4
Deliveries and Transactions. At the Closing, the following transactions shall occur (the “Transactions”), which
Transactions shall be deemed to take place simultaneously and no Transaction shall be deemed to have been completed or any document described
in this Section 2.2.4 delivered until all such Transactions have been completed and all required documents delivered:


 


2.2.4.1
Issuance by BioTime to HBL of the Traded Stock in accordance with Section 1.3 above. In the event that HBL delivers to BioTime
a Trustee Tax Certificate (as defined below) at or prior to Closing, then upon receipt thereof, BioTime shall deposit, or cause to be
deposited, with a trustee appointed by HBL (the “Trustee”), such number of Traded Stock in accordance of Sections
1.2 and 1.3 (the “Closing Payment Fund”). For the purpose of this Agreement, “Trustee Tax Certificate”
means a certificate or ruling of exemption of withholding tax or arrangement to pay, or a deferral of payment of any taxes required to
be so paid by HBL, issued by relevant tax authority whereby all responsibility for payment of any taxes required to be so paid by HBL
shall fall of the Trustee and exempting BioTime from the duty to withhold any tax, in a form and substance acceptable to BioTime.


 


2.2.4.2
HBL shall have delivered to BioTime (i) a Trustee Tax Certificate, or (ii) HBL Tax Certificate (as defined below) exempting BioTime from
the duty to withhold any tax on the Closing date, or (iii) an amount in cash equal to [ * ].


 


2.2.4.3
HBL shall be provided a warrant to purchase such number of Ordinary Shares of Cell Cure, par value NIS 0.01 each, equal to 5% (five percent)
of Cell Cure’s issued and outstanding share capital on a fully diluted basis (excluding any outstanding options issued under Cell
Cure’s option plan and any shares reserved for issuance thereunder and the conversion of the [ * ] Loans) as of the Closing, substantially
in the form attached hereto as Exhibit B (the “Debt Warrant”).


 


2.2.4.4
The execution and delivery by HBL and BioTime of the Share Purchase and Transfer Agreement between the parties hereto to which this Agreement
forms an attachment (the “SPA”), and consummation of the Closing thereunder (as such term is defined therein).


 


2.2.4.5
The Board shall have approved the transactions contemplated hereunder, including the assignment of the Cell Cure Debt and the obligations
of Cell Cure hereunder (the “Board Consent”), and BioTime shall have delivered to HBL a true and correct copy of such
Board Consent.


 


2.2.4.6
BioTime shall have delivered HBL a written confirmation of Cell Cure confirming the assumption of HBL’s rights and obligations
under the Loan Documents by BioTime in accordance with the terms and conditions set forth in this Agreement, and that the transactions
contemplated by this Agreement, including the sale of the Cell Cure Debt, were duly authorized and approved by the Board and are in compliance
with Cell Cure’s Articles and organizational documents.


 


2.2.4.7
BioTime shall have provided HBL evidence satisfactory to HBL, that Cell Cure’s Convertible Loans have been converted into non-convertible
loans and that the Cell Cure’s Loan Documents have been amended accordingly, all in accordance with Section 1.8 above.


 


2.2.4.8
The Registration Statement (as defined below) for the Traded Stock filed in accordance with Section 7.1, being declared effective
by the Securities and Exchange Commission (the “SEC”).


 




    	-15-



    	 



    

 


2.3
Cell Cure Organizational Documents.


 


2.3.1
Following the Closing, BioTime shall ensure that (i) Cell Cure’s shareholders adopt the amendment to Cell Cure’s Articles
or a new set of articles, in the form attached hereto as Exhibit E (the “ Cell Cure’s Amended Articles”),
providing, inter alia, that the issuance of the Debt Warrant, Investment Warrants and any shares issuable upon exercise thereof
and the transfer of shares by BioTime to HBL under the BioTime Call Option(s), shall not be subject to any pre-emptive rights or rights
of first refusal of Cell Cure’s shareholders, as applicable; and (ii) the Shareholders Agreement is terminated. tBioTime shall
provide HBL evidence satisfactory to HBL, that the obligations under this Section 2.3.1 have been performed, within ninety (90)
days following the Closing date.


 


2.3.2
BioTime shall ensure that item (v) in the definition of New Securities, as it pertains to HBL as well as Articles 20.7 and 58 of Cell
Cure’s Amended Articles as set forth in Section 2.3.1 above and the amendment to Cell Cure’s Loan Documents, as contemplated
by Section 2.3.1 and 2.2.4.7 respectively, shall remain in full force and effect until the later of (i) the end of the
Qualifying Period, and (ii) the expiration and\or exercise of the Debt Warrant and\or the Investment Warrant(s) held by HBL, if any.


 


3.
Representations and Warranties of BioTime. BioTime hereby makes the following representations and warranties to HBL:


 


3.1
BioTime has the requisite power and authority to enter into this Agreement and to consummate the transactions contemplated hereby and
otherwise to carry out its obligations hereunder. This Agreement, and any ancillary document hereto, when executed and delivered by BioTime,
shall be duly and validly authorized, executed and delivered by BioTime and constitute the valid and legally binding obligations of BioTime,
legally enforceable against it in accordance with its terms, subject, however, to applicable bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and similar laws of general applicability relating to or affecting creditor’s rights and to general
equitable principles.


 


3.2
As the majority shareholder of Cell Cure, it is familiar with the condition and operations of Cell Cure and in addition, has had the
opportunity to ask questions of and receive answers from and/or obtain additional information from, the management of Cell Cure concerning
the financial and other affairs of Cell Cure.


 


3.3
BioTime has obtained the requisite consents, approvals and/or agreement of any individual or entity as required to be obtained by BioTime
to execute and perform this Agreement or any agreements, instruments or other obligations entered into in connection with this Agreement,
and the transaction contemplated hereby and thereby, including the issuance of the Traded Stock to HBL pursuant to Section 1.3.


 


3.4
The Traded Stock to be issued pursuant to this Agreement will not be issued in violation of any preemptive rights, right of first refusal
and\or any other rights of the current or past shareholders of BioTime, or any agreement to which BioTime was or is a party or bound.
When issued and delivered in accordance with this Agreement, the Traded Stock shall be (a) duly and validly authorized, issued and outstanding
in compliance with all applicable federal or state securities laws, fully paid and non-assessable, and issued in compliance with all
applicable federal or state securities laws (b) listed for trading on the NYSE MKT and will be able to be sold under the Registration
Statement assuming compliance the prospectus delivery requirements and (c) free and clear of any liens, claims, charges, rights, pledges,
security interests, mortgages, options, title defects or other encumbrances, restrictions or limitations of any nature whatsoever or
other security interest of any kind or character or any right of any third party.


 


3.5
All registration statements, certifications, forms, reports and other documents (the “Company Reports”) filed by BioTime
with the SEC: (i) complied in all material respects with the applicable requirements of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), Securities Act of 1933, as amended (“Securities Act”), and the Sarbanes-Oxley
Act of 2002 (the “Sarbanes-Oxley Act”), as the case may be, and the rules and regulations thereunder applicable to
such Company Reports at the time such Company Report was filed or submitted with the SEC; and (ii) did not contain any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading. Since January 1, 2015, BioTime has been in compliance in
all material respects with (i) the applicable provisions of the Securities Act, the Exchange Act and the Sarbanes-Oxley Act (and (ii)
the applicable listing and corporate governance rules and regulations of NYSE MKT and other requirements of the California Corporations
Code.


 




    	-16-



    	 



    

 


3.6
The consolidated financial statements (including any related notes) contained in the Company Reports: (i) complied as to form in all
material respects with any applicable law and the published rules and regulations of the SEC applicable thereto; (ii) were prepared in
accordance with US GAAP applied on a consistent basis throughout the periods covered (except as may be indicated in the notes to such
financial statements and except that the unaudited financial statements may not contain footnotes and are subject to normal and recurring
year-end adjustments that will not, individually or in the aggregate, be material in amount), and (iii) fairly presented, in all material
respects, the consolidated financial position of BioTime as of the respective dates thereof and the results of operations and cash flows
of BioTime for the periods covered thereby.


 


4.
Representations and Warranties of HBL. HBL hereby makes the following representations and warranties to BioTime:


 


4.1
HBL is the sole owner of the Cell Cure Debt and has not granted rights therein to any third party.


 


4.2
HBL has the requisite power and authority to enter into this Agreement and to consummate the transactions contemplated hereby and otherwise
to carry out its obligations hereunder. This Agreement, and any ancillary document hereto, when executed and delivered by HBL, shall
be duly and validly authorized, executed and delivered by HBL and constitute the valid and legally binding obligations of HBL, legally
enforceable against it in accordance with its terms, subject, however, to applicable bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability relating to or affecting creditor’s rights and to general equitable principles.


 


4.3
HBL has obtained the requisite consents, approvals and/or agreement of any individual or entity as required to be obtained by HBL in
connection with the execution and performance by HBL of this Agreement or the execution and performance by HBL of any agreements, instruments
or other obligations entered into in connection with this Agreement, including, but not limited to, any authorizations required from
the Israeli Securities Authority, if any.


 


5.
Publication.


 


The
parties have agreed this Agreement and the transaction contemplated hereunder are confidential and shall not be disclosed by either party.
Accordingly, neither party shall issue any press release, statement or other disclosure regarding this Agreement other than as set forth
in Exhibit D attached hereto or such other disclosure as shall be agreed upon the parties. The above limitation shall not apply
to the extent that such disclosure is required under applicable securities law or regulation (including the Exchange Act) or the Tel-Aviv
Stock Exchange rules.


 


6.
Termination.


 


This
Agreement shall be terminated upon the termination of the SPA, provided that Section 1.5 shall survive the termination of this
Agreement and shall remain in full force and effect in accordance with its terms.


 


7.
Registration Rights.


 


7.1
Within fifteen (15) days from the Effective Date, unless otherwise agreed upon in writing by HBL and BioTime), BioTime shall file with
the SEC a registration statement on a Form S-3 to register for resale the Traded Stock with the SEC (“Registration Statement”)
and shall provide HBL with a copy of the Registration Statement within two (2) business day from the date of filing the Registration
Statement with the SEC. Prior to filing such Registration Statement, BioTime shall give HBL a reasonable opportunity to review and comment
on the Registration Statement, and BioTime agrees to include all reasonable comments provided by HBL or its legal counsel. BioTime’s
obligation to file the Registration Statement shall be dependent upon HBL’s providing the information necessary for BioTime to
include in the Registration Statement relating to HBL’s capacity as a selling stockholder thereunder.


 




    	-17-



    	 



    

 


7.2
BioTime shall use its commercially reasonable efforts to cause such Registration Statement to become effective and keep such registration
statement effective until all the securities covered by such Registration Statement may be freely traded by HBL without volume restrictions
under Rule 144 promulgated under the Securities Act (“Rule 144”). BioTime shall use its commercially reasonable efforts
to cause all securities covered by such Registration Statement to be listed on the NYSE MKT.


 


7.3
All expenses incurred in connection with the Registration Statement, including all registration, filing, and qualification fees; printers’
and accounting fees; fees and disbursements of counsel for BioTime, shall be borne by the [ * ] shall be responsible for the fees and
expenses of its own legal counsel in connection with the Registration Statement.


 


7.4
With a view to making available to the HBL the benefits of Rule 144, BioTime shall:


 


7.4.1
make and keep available adequate current public information, as those terms are understood and defined in Rule 144, at all times after
the effective date of the Registration Statement;


 


7.4.2
use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of BioTime under
the Securities Act and the Exchange Act; and


 


7.4.3
furnish to HBL, so long as HBL owns any Traded Stock, forthwith upon request (i) to the extent accurate, a written statement by BioTime
that it has complied with the reporting requirements of Rule 144, the Securities Act, and the Exchange Act, or that it qualifies as a
registrant whose securities may be resold pursuant to Form S-3; and (ii) such other information as may be reasonably requested in availing
HBL of any rule or regulation of the SEC that permits the selling of any such securities without registration or pursuant to Form S-3.


 


7.5
Indemnification.


 


7.5.1
To the extent permitted by law, BioTime will indemnify and hold harmless HBL, and the officers, directors and shareholders of HBL, legal
counsel and accountants for HBL; any underwriter (as defined in the Securities Act) for HBL; and each Person, if any, who controls HBL
or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages (as defined below), and BioTime will
pay to HBL, underwriter, controlling individual, corporation, partnership, trust, limited liability company, association or other entity
(collectively, “Person”), or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection
with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided, however,
that the indemnity agreement contained in this subsection shall not apply to amounts paid in settlement of any such claim or proceeding
if such settlement is effected without the consent of BioTime, at its discretion, nor shall BioTime be liable for any Damages to the
extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information
furnished by or on behalf of HBL, underwriter, controlling Person, or other aforementioned Person. “Damages” means
any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange
Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of
or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of
BioTime or HBL, as applicable, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements
thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the
statements therein not misleading; or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates
(as defined in Cell Cure’s Articles)) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation
promulgated under the Securities Act, the Exchange Act, or any state securities law.


 


7.5.2
To the extent permitted by law, HBL will indemnify and hold harmless BioTime and each of its directors, each of its officers who has
signed the registration statement, each Person (if any), who controls BioTime within the meaning of the Securities Act, legal counsel
and accountants for BioTime, any underwriter (as defined in the Securities Act), and any controlling Person of any such underwriter,
against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance
upon and in conformity with written information furnished by or on behalf of HBL; and HBL will pay to BioTime and each other aforementioned
Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding
from which Damages may result, as such expenses are incurred; provided, however, that the indemnity agreement contained in this subsection
shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of HBL,
at its discretion; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution
under this subsection (ii) or subsection (iv) below exceed the proceeds from the offering received HBL (net of any selling expenses paid
by HBL), except in the case of fraud or willful misconduct by HBL.


 




    	-18-



    	 



    

 


7.5.3
Promptly after receipt by an indemnified party under this Section 7.5 of notice of the commencement of any action (including any
governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect
thereof is to be made against any indemnifying party under this Section 7.5, give the indemnifying party notice of the commencement
thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires,
participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel
mutually satisfactory to the parties; provided, however, that an indemnified party (together with all other indemnified parties that
may be represented without conflict by one counsel) shall have the right to retain one separate counsel, at its expense unless representation
of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential conflict
of interest between such indemnified party and any other party represented by such counsel in such action. The failure to give notice
to the indemnifying party will not relieve it of any liability that it may have to any indemnified party except if such failure shall
have materially prejudiced the indemnifying party.


 


7.5.4
To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party
otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 7.5 but it is judicially
determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the
denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section
7.5 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party
hereto for which indemnification is provided under this Section 7.5, then, and in each such case, such parties will contribute
to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such
proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection
with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect
any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined
by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged
omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’
relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided, however,
that, in any such case (x) HBL shall not be required to contribute any amount in excess of the public offering price of all such Traded
Stock offered and sold by HBL pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within
the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent
misrepresentation; and provided further that in no event shall HBL’s liability pursuant to this subsection (iv), when combined
with the amounts paid or payable by HBL pursuant to subsection (ii), exceed the proceeds from the offering received by HBL (net of any
selling expenses paid by HBL), except in the case of willful misconduct or fraud by HBL.


 


8.
Miscellaneous.


 


8.1
Entire Agreement; Amendment. This Agreement and the schedule and exhibits hereto, constitute the full and entire understanding
and agreement between the parties with regard to the subject hereof, and no party shall be liable or bound to any other party in an manner
by any warranties, representations or covenants except as specifically set forth herein or therein. Neither this Agreement nor any term
hereof may be amended, waived or discharged other than by a written instrument signed by all the parties hereto.


 


8.2
Notices. All notices and other communications given or made pursuant hereto shall be in writing, in English and shall be deemed
effectively given: (i) upon delivery to the party if delivered personally or via courier; (ii) when sent by confirmed electronic mail
or facsimile if sent during normal business hours of the recipient; if not, then on the next business day; or (iii) on the date set forth
on the return receipt, if sent by registered or certified mail, return receipt requested, postage prepaid. All notices and communications
shall be sent to the parties at the addresses set forth on the signature page below (or at such other addresses as shall be specified
by notice given in accordance with this Section 8.2).


 




    	-19-



    	 



    

 


8.3
Assignment. Neither party may assign, convey or transfer any of its rights or obligations under this Agreement; provided, that
HBL may assign it rights hereunder to any of its Affiliates (as such term is defined in Cell Cure’s Articles).


 


8.4
Delays or Omissions. No delay or omission to exercise any right, power, or remedy accruing to any party upon any breach or default
under this Agreement shall be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit,
consent, or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on
the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent
specifically set forth in such writing.


 


8.5
Severability. In the event that any provision of this Agreement becomes or is declared by a court of competent jurisdiction to
be illegal, unenforceable or void, this Agreement shall continue in full force and effect without the said provision; provided,
however, that in such event this Agreement shall be interpreted so as to give effect, to the greatest extent consistent with and
permitted by applicable law, to the meaning and intention of the excluded provision as determined by such court of competent jurisdiction.


 


8.6
Expenses; taxes. Each party shall bear all taxes incurred by it in connection with the Transactions and for which such party is
statutorily liable. However, in the event that BioTime is required to withhold income taxes at source with respect to the transfer of
the Traded Stock pursuant to Section 2.2.4.2 above, BioTime shall have the right to withhold such amounts as required under applicable
tax law at the applicable rate for such withholding in accordance with applicable law or a HBL Tax Certificate providing for a reduced
rate. “HBL Tax Certificate” means a certification or ruling of exemption of withholding tax and/or proof of payment,
or arrangement to pay, or a deferral of payment of any taxes required to be so paid by HBL, issued by relevant tax authority, in a form
and substance acceptable to BioTime.


 


8.7
Representation; waiver of conflict of interest. Each party hereto acknowledges that it has had the opportunity to obtain independent
legal and tax advice prior to executing this Agreement and fully understands all provisions of this Agreement. HBL and BioTime recognize
and acknowledge that counsel to BioTime also represents Cell Cure in connection with various legal matters and each of BioTime and HBL
waive any conflict of interest or other allegations in this regard.


 


8.8
Governing Law and Jurisdiction. This Agreement shall be governed in all respects by the laws of the State of Israel. Any proceeding
regarding a dispute arising under or in relation to this Agreement shall be resolved solely and exclusively in the competent court located
(i) in the city of Tel Aviv, Israel, if such proceeding is initiated by BioTime, and (ii) in the city of New York, New York, if such
proceeding is initiated by HBL, and each of the parties hereto hereby irrevocably submit to the exclusive jurisdiction of such venue.


 


8.9
Counterparts. This Agreement may be executed in any number of counterparts and the executed signature pages sent to the other
parties by facsimile transmission or PDF shall be binding as evidence of such party’s agreement hereto and acceptance hereof.


 


[SIGNATURE
PAGE FOLLOWS]


 




    	-20-



    	 



    

 


IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.


 


	 	 	 
	BioTime
    Inc.	 	HBL-Hadasit
    Bio-Holdings Ltd.
	 	 	 
	Name:
    Aditya P. Mohanty	 	Name:
    Baruch Halpert
	Title:
    Co-CEO	 	Title:
    Chairman
	 	 	 
	1010
    Atlantic Ave., Suite 102	 	Jerusalem
    Bio-Park, 5th Floor
	Alameda,
    CA 94501	 	Hadassah
    Ein-Kerem Campus,
	USA	 	Jerusalem
    91120
	 	 	Israel
	 	 	 
	Facsimile:	 	 	 	Facsimile:	 	 
	E-mail:	 	 	 	E-mail:	 	 
	Attn:	 	 	 	Attn:	 	 


 




    	-21-



    	 



    

 


EXHIBIT
A


 


CELL
CURE DEBT


 


	Loan
    document	 	Remittance
    Date	 	Amount
    of loan remitted (in US$)
	Subscription
    Offer dated May 8, 2014	 	September
    9, 2014	 	[
    * ]
	 	September
    1, 2015	 	[
    * ]
	 	April
    2, 2015	 	[
    * ]
	 	 	 	 	 
	Subscription
    Offer dated November 10, 2015	 	February
    14, 2016	 	[
    * ]
	 	February
    21, 2016	 	[
    * ]
	 	April
    19, 2016	 	[
    * ]
	 	June
    14, 2016	 	[
    * ]
	 	 	 	 	 
	Loan
    Agreement dated October 5,	 	August
    25, 2016	 	[
    * ]
	2016,
    as amended on November 29,	 	October
    6, 2016	 	[
    * ]
	2016
    and the promissory notes dated	 	 	 	 
	(1)
    August 25, 2016 and (2) October 6,	 	 	 	 
	2016.	 	 	 	 
	 	 	 	 	 
	Loan
    Agreement dated, December 11, 2016 and the promissory note dated December 13, 2016	 	December
    13, 2016	 	[
    * ]
	 	 	 	 	 
	Loan
    Agreement dated March 21, 2017 and the promissory note dated March 29, 2017.	 	March
    29, 2017	 	[
    * ]
	 	 	 	 	 
	Loan
    Agreement dated March 30, 2017, and the promissory note dated April 24, 2017.	 	April
    24, 2017	 	[
    * ]


 




    	-22-



    	 



    

 


Execution
Copy


 


EXHIBIT
B


 


THIS
WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT AND HAVE NOT BEEN REGISTERED
UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED OR UNDER ANY APPLICABLE U.S. STATE SECURITIES LAWS OR COMPARABLE SECURITIES LAW OF
A NON-U.S. JURISDICTION (COLLECTIVELY, THE “SECURITIES LAWS”). THEY MAY NOT BE OFFERED FOR SALE, SOLD, CONVEYED, TRANSFERRED,
PLEDGED, GIFTED, ASSIGNED, ENCUMBERED OR OTHERWISE DISPOSED OF UNLESS (1) REGISTERED UNDER SUCH SECURITIES LAWS, OR (2) PURSUANT TO AVAILABLE
EXEMPTIONS FROM REGISTRATION UNDER SUCH SECURITIES LAWS AND THE RULES PROMULGATED THEREUNDER, PROVIDED THAT THE HOLDER DELIVERS TO THE
COMPANY AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY, CONFIRMING THE AVAILABILITY OF SUCH EXEMPTION.


 


Date
of Issuance: _____________, 2017


 


WARRANT
TO PURCHASE ORDINARY SHARES


OF
CELL CURE NEUROSCIENCES LTD.


(THE
“WARRANT”)


 


THIS
CERTIFIES THAT, for value received, the receipt and sufficiency of which is hereby acknowledged, HBL-Hadasit Bio-Holdings Ltd., (the
“Holder”) is entitled to purchase, at the Exercise Price (as such term is defined in Section 2 below) and at any time
and from time to time until the Expiration Date (as defined in Section 2 hereof), such number of Ordinary Shares, nominal value NIS 0.01
each (the “Ordinary Shares”) of Cell Cure Neurosciences Ltd. (the “Company”) as set forth herein,
subject to the provisions and upon the terms and conditions hereinafter set forth in this Warrant, being issued to the Holder pursuant
to that certain Debt and Note Purchase Agreement, dated June 16, 2017 (the “Debt Purchase Agreement”).


 


1.
Number & Class of Warrant Shares; Exercise Price & Period.


 


(a)
Number of Warrant Shares; Exercise Price. The Holder will be entitled to purchase up to 24,566 Ordinary Shares (the “Warrant
Shares”) at an exercise price per each Warrant Share of US$40.5359 (the “Exercise Price”):


 


(b)
Vesting. The Warrant Shares shall be fully vested upon the Date of Issuance, set forth above.


 


(c)
Exercise Period. This Warrant (and all rights of the Holder hereunder) will expire and will no longer be exercisable upon the
earlier to occur of: (i) the lapse of 5 (five) years from the Date of Issuance, (ii) immediately prior to the closing of a Corporate
Transaction or (iii) immediately prior to the closing of an IPO (the “Expiry Date”); provided that in the case of
clause (ii) and (iii), the Company shall notify the Holder of such event by providing the Holder a written notice by no later than fifteen
(15) days prior to the closing of an IPO or Corporate Transaction, as applicable.


 


(d)
Adjustment. If the outstanding shares of the class or series of shares issuable upon exercise hereof shall be subdivided into
a greater number of shares, the Exercise Price in effect immediately prior to such subdivision shall simultaneously with the effectiveness
of such subdivision, be proportionately reduced. If the outstanding shares of the class or series of shares issuable upon exercise hereof
shall be combined into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall, simultaneously
with the effectiveness of such combination, be proportionately increased. When any adjustment is required to be made in the Exercise
Price, in accordance herewith, the number of Warrant Shares purchasable upon the exercise of this Warrant shall be changed to the number
determined by dividing (i) an amount equal to the number of Warrant Shares issuable upon the exercise of this Warrant immediately prior
to such adjustment, multiplied by the Exercise Price in effect immediately prior to such adjustment, by (ii) the Exercise Price in effect
immediately after such adjustment. In case at any time or from time to time on or after the date hereof the holders of the class of shares
of which the Warrant Shares are a part, shall have received or, on or after the record date fixed for the determination of eligible shareholders,
shall have become entitled to receive, without payment therefor, other or additional securities of the Company by way of dividend, bonus
shares or other distribution, then, and in each case, the Holder shall, upon the exercise of this Warrant, be entitled to receive, in
addition to the number of Warrant Shares receivable thereupon, and without payment of any additional consideration therefor, the amount
of such other or additional securities of the Company which such Holder would be entitled to receive had it been the holder of record
of such Warrant Shares on the date hereof and had thereafter, during the period from the date hereof to and including the date of such
exercise, retained such shares and/or all other additional shares receivable by it as aforesaid during such period.


 




    	-23-



    	 



    

 


(e)
For the purpose of this Warrant, the following terms are defined as follows:


 


“IPO”
means an initial underwritten public offering of the Shares of the Company pursuant to an effective registration statement under the
United States Securities Act of 1933, as amended or the Israeli Securities Law, 5728-1968, as amended or equivalent law of another jurisdiction


 


“Corporate
Transaction” means the consummation of any of the following transactions or series of related transactions to which the Company
is a party: (i) A merger, acquisition, reorganization or consolidation in which the Company is not the surviving entity (or survives
only as a subsidiary of another entity whose shareowners did not own all or substantially all of the shares in substantially the same
proportions as immediately prior to such transaction), except for a transaction the principal purpose of which is to change the jurisdiction
in which the Company is incorporated; or (ii) the sale, transfer, exchange or other disposition of all or substantially all of the shares
or assets of the Company (including, intellectual property rights which, in the aggregate, constitute substantially all of the Company’s
material assets), in a transaction not covered by the exception to clause (i) above; provided, however, that a bona fide
private equity financing of the Company, which does not fall under Section (i) or (ii) above, shall not constitute a Corporate Transaction
hereunder.


 


2.
Method of Exercise; Payment; Redemption.


 


(a)
Prior to the Expiry Date, this Warrant may be exercised by the Holder, in whole or in part), by the surrender of this Warrant, with a
duly executed notice of exercise in the form attached hereto as Exhibit A (the “Notice of Exercise”)
at the principal office of the Company, accompanied by the payment to the Company, by cash, wire transfer or such other method acceptable
to the Company, of an amount equal to the applicable Exercise Price under Section 1(a) above.


 


(b)
In the event that the Holder does not provide the Company with the Notice of Exercise and effect the payment in consideration for the
Warrant Shares purchased by such Holder prior to the Expiry Date, then such Holder shall be deemed to have waived its rights under this
Warrant.


 


(d)
The exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which this
Warrant is surrendered to the Company as provided in Section 2(a) above, and the Holder shall be deemed the holder of record of the Warrant
Shares as of such date.


 


(e)
In the event of any exercise of this Warrant in accordance with the terms hereof, the Company shall (i) issue the Warrant Shares to the
Holder; (ii) deliver to the Holder share certificate(s) evidencing the Warrant Shares (iii) register the Holder in its register of shareholders;
and (iv) notify the Israeli Companies Registrar of such issuance. In the event of a partial exercise of this Warrant, the Company shall
concurrently issue to the Holder a replacement warrant on the same terms and conditions of this Warrant, which shall be dated as of the
date hereof, covering the number of Warrant Shares in respect of which this Warrant shall not have been exercised.


 




    	-24-



    	 



    

 


2A.
Net Issue Exercise.


 


(a)
Notwithstanding the foregoing, in lieu of payment of the Exercise Price per Warrant Share as set forth in Section 2(a) above, the Holder
may elect to receive, for no additional consideration, Warrant Shares equal to the value of this Warrant, or any portion of the Warrant
which the Holder requests to exercise, by surrender of this Warrant at the principal office of the Company together with executed Notice
of Exercise reflecting such election, in which event the Company shall issue to the Holder a number of Warrant Shares computed using
the following formula:




 


	 	 	Y
                                            (A-B)

    X
    = ———————

    A

	 	 	 	 	 	 
	Where:	 	X	 	=	the
    number of Warrant Shares to be issued to the Holder.
	 	 	 	 	 	 
	 	 	Y	 	=	the
    number of Warrant Shares underlying the portion of this Warrant which the Holder requests to exercise pursuant to this Section 2A.
	 	 	 	 	 	 
	 	 	A	 	=	the
    per share Fair Market Value (as defined below) of a Warrant Share as of the date of exercise pursuant to this Section 2A.
	 	 	 	 	 	 
	 	 	B	 	=	The
    per shares Exercise Price of a Warrant Share issuable under this Warrant, as in effect on the date of exercise pursuant to this Section
    2A.


 


(i)
In no event shall a Net Issue Exercise be settled in cash.


 


For
example, if the Holder elects to exercise this Warrant pursuant to this Section 2A, with respect to 10,000 Warrant Shares
(i.e. Y=10,000), and assuming that the per share Fair Market Value of a Warrant Share as of the exercise date is US$80 (i.e.
A=80), and the per share Exercise Price of a Warrant Share as of the exercise date is US$40.5359 (i.e. B=40.5359), then the
Company shall issue to the Holder 4,933 Warrant Shares upon such exercise (i.e. X=4,933).


 


(b)
Fair Market Value. For purposes of this Section 2A, the per share “Fair Market Value” of the Warrant Shares shall
mean:


 


(i)
If the Company’s Ordinary Shares are publicly traded and listed on a stock exchange, the per share Fair Market Value of the Warrant
Shares shall be the average of the closing prices of the Ordinary Shares as quoted on the principal exchange on which the Ordinary Shares
are listed, in each case for the 15 (fifteen) trading days ending five trading days prior to the date of exercise pursuant to this Section
2A;


 


(ii)
If the Ordinary Shares are not publicly traded and:


 


(1)
the exercise date is immediately prior to the closing of an IPO, then the Fair Market Value shall be offer price of the IPO for each
Ordinary Share of the Company with the exercise of Warrant and issuance of the Warrant Shares shall be deemed to have taken place immediately
prior to the closing of the IPO.


 


(2)
the exercise date is immediately prior to the closing of a Corporate Transaction, then the per share Fair Market Value of the Warrant
Shares shall the price per Warrant Share as determined as part of such Corporate Transaction.


 


(3)
otherwise, as shall be determined in good faith by the Company’s Board of Directors (the “Board”) and described
in a written notice delivered by the Company to the Holder within five (5) days following the date of exercise pursuant to this Section
2A (the “Fair Market Value Notice”); provided, however, that the Holder shall be entitled to object to such determination
by delivering a written notice to the Company to that effect (an “Objection Notice”), in which event the Fair Market
Value shall be determined by an independent appraiser selected by the Company and the Holder, whose costs of engagement shall be borne
by the Holder If an Objection Notice is not delivered by the Holder to the Company within twenty (20) days after delivery by the Company
of the Fair Market Value Notice to the Holder, such failure to so object will be deemed an irrevocable waiver and release by the Holder
of the Company, its shareholders, officers, directors, employees, representatives, legal counsel and affiliated entities, from all claims,
demands, liabilities, damages, losses, costs and expenses in connection with the determination of the Fair Market Value by the Board.


 




    	-25-



    	 



    

 


3.
Shares Fully Paid; Reservation of Shares. All of the Warrant Shares issuable upon the exercise of this Warrant will, upon
issuance and receipt of the Exercise Price therefore, be validly issues, fully paid and non-assessable, and free from all liens, charges,
claims, encumbrances, preemptive rights, rights of first refusal or similar rights, or any other third party rights with respect thereto.
At all times prior to the Expiry Date, the Company will have authorized and reserved for issuance sufficient shares, free from pre-emptive
rights to provide for the exercise of this Warrant, so that this Warrant may be exercised without additional authorization of share capital.
The Company will not by amendment of its Articles of Association or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issuance or sale of its securities or any other action, avoid, or seek to avoid, the observance or performance of any of
the terms to be observed or performed hereunder, but will at all times in good faith assist in the carrying out of all provisions hereof
and in taking of all such actions as may be necessary or appropriate in order to protect the rights of the Holder hereunder against any
impairment.


 


4.
Lock-Up. In the event of an IPO, the Warrant Holder agrees that the Warrant Shares shall be subject to a “lock-up”
period on the same terms and conditions as shall be applicable to other shareholders of the Company.


 


5.
Fractional Shares. No fractional shares will be issued in connection with any exercise of this Warrant. In the event of
fractional shares, the Company will round up the number of Warrant Shares issuable upon such exercise to the nearest whole share (with
one-half being rounded upward).


 


6.
No Public Market in Shares. The Holder acknowledges that no public market now exists for any of the Warrant Shares and
that the Company has made no assurances that a public market will ever exist for the Company’s shares. The Holder further acknowledges
that it is an experienced investor and that it is fully capable of assessing the risks of exercising the Warrant Shares and of bearing
the economic risks of doing so.


 


8.
No Transferability. Neither party may assign, convey or transfer any of its rights or obligations under this Warrant; provided,
that the Holder may assign this Warrant and its rights hereunder to any of its Affiliates (as such term is defined in the Debt Purchase
Agreement).


 


9.
No Rights of Shareholders. Except as otherwise provided in the Debt Purchase Agreement, this Warrant, does not, by itself,
entitle the Holder to any rights (voting or otherwise) as a shareholder of the Company. In the absence of affirmative action by the Holder
to acquire Warrant Shares by exercise of this Warrant, no provisions of this Warrant shall cause the Holder to be a shareholder of the
Company for any purpose.


 


11.
Loss, Theft, Destruction or Mutilation of Warrant. If this Warrant is lost, stolen, destroyed or mutilated, the Company
will execute and deliver to the Holder a replacement warrant of like date, tenor, and denomination upon receipt by the Company of (a)
evidence satisfactory to the Company of the occurrence of such event; and (b) (i) in the event of mutilation, upon surrender and cancellation
of this Warrant; or (ii) in the event of loss, theft, or destruction of this Warrant, of indemnity reasonably satisfactory to the Company.


 


12.
Taxes. Each party acknowledges and agrees that any and all tax imposed on such party in connection with this Warrant,
including with relation to the grant hereof, the exercise of the Warrant Shares, and the sale of the Warrant Shares shall be borne solely
by such party, and such party will be solely liable for all such tax.


 


13.
Headings. The headings contained in this Warrant have been inserted as a matter of convenience, do not form part,
and will not affect construction of, this Warrant.


 


14.
Governing Law; Jurisdiction. This Warrant and all matters arising out of or in connection with this Warrant will be governed
by, and construed in accordance with, the laws of the State of Israel, without reference to its conflict of laws principles. Any proceeding
regarding a dispute arising under or in relation to this Agreement will be resolved exclusively in the competent courts of (i) Tel Aviv-Jaffa
if such proceeding is initiated by BioTime, and (ii) in the city of New York, New York, if such proceeding is initiated by HBL, and the
Company and the Holder hereby irrevocably submits to the sole and exclusive jurisdiction of such courts.


 


15.
Partial Invalidity. If any provision of this Warrant is held by a court of competent jurisdiction to be invalid or unenforceable
under applicable law, then such provision will be excluded from this Warrant and the remainder of this Warrant will be interpreted as
if such provision were so excluded and will be enforceable in accordance with its terms; provided, however, that in such event this Warrant
will be interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and
intention of the excluded provision.


 


16.
Entire Agreement. The Debt Purchase Agreement and this Warrant constitute the entire agreement between the Holder and the
Company relating to the subject matter addressed herein, and supersedes all prior communications, contracts or agreements, whether oral
or written.


 


17.
Counterparts. This Warrant may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Facsimile and/or PDF signatures of a party shall be binding as evidence
of such party’s agreement hereto and acceptance hereof.


 


[Signature
Page to Follow]


 




    	-26-



    	 



    

 


IN
WITNESS WHEREOF, the parties have executed this Warrant as of the date above written.


 


	Cell Cure Neurosciences Ltd.	 
	 	 	 
	By:		 
	 	Dr. Charles Irving	 
	Title:	CEO	 


 


	 	Agreed
    and accepted:
	 	 
	 	 
	 	HBL-Hadasit
    Bio-Holdings Ltd.


 


	 	By:	 
	 	Title:	 


 




    	-27-



    	 



    

 


EXHIBIT
A


NOTICE
OF EXERCISE


 


To:


Cell
Cure Neurosciences Ltd.


Hadassah
Medical Center


POB
12000


Jerusalem,
91120


Israel


 


Attn:
Chief Executive Officer


 


1.
Pursuant to that certain Warrant to Purchase Ordinary Shares of Cell Cure Neurosciences Ltd., the undersigned hereby elects:


 


[check
the box that applies]


 


	 	☐	to
    exercise the Warrant and purchase ____ Warrant Shares (as defined therein), and tenders herewith payment in full for the purchase
    price of the Warrant Shares being purchased.
	 	 	 
	 	☐	to
    exercise this Warrant with respect to ___ Warrant Shares by net exercise election pursuant to Section 2A of the Warrant.


 


2.
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned, and record same in the Company’s
internal share registry.





 


	 	Very
    truly yours,
	 	 
	 	 
	 	HBL-Hadasit
    Bio-Holdings Ltd.


 


	 	By:	 
	 	Title:	 


 




    	-28-



    	 



    

 


EXHIBIT
C


 


THIS
WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN ACQUIRED SOLELY FOR INVESTMENT AND HAVE NOT BEEN REGISTERED
UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED OR UNDER ANY APPLICABLE U.S. STATE SECURITIES LAWS OR COMPARABLE SECURITIES LAW OF
A NON-U.S. JURISDICTION (COLLECTIVELY, THE “SECURITIES LAWS”). THEY MAY NOT BE OFFERED FOR SALE, SOLD, CONVEYED, TRANSFERRED,
PLEDGED, GIFTED, ASSIGNED, ENCUMBERED OR OTHERWISE DISPOSED OF UNLESS (1) REGISTERED UNDER SUCH SECURITIES LAWS, OR (2) PURSUANT TO AVAILABLE
EXEMPTIONS FROM REGISTRATION UNDER SUCH SECURITIES LAWS AND THE RULES PROMULGATED THEREUNDER, PROVIDED THAT THE HOLDER DELIVERS TO THE
COMPANY AN OPINION OF COUNSEL, SATISFACTORY TO THE COMPANY, CONFIRMING THE AVAILABILITY OF SUCH EXEMPTION.


 


Date
of Issuance: ______________, ____


 


WARRANT
TO PURCHASE SHARES


OF
CELL CURE NEUROSCIENCES LTD.


(THE
“WARRANT”)


 


THIS
CERTIFIES THAT, for value received, the receipt and sufficiency of which is hereby acknowledged, HBL-Hadasit Bio-Holdings Ltd., (the
“Holder”) is entitled to purchase, at the Exercise Price (as such term is defined in Section 2 below) and at any time
and from time to time until the Expiration Date (as defined in Section 2 hereof), such number of [_________insert type of Shares],
nominal value NIS 0.01 each (the “Shares”) of Cell Cure Neurosciences Ltd. (the “Company”) as set
forth herein, subject to the provisions and upon the terms and conditions hereinafter set forth in this Warrant, being issued to the
Holder pursuant to that certain Debt and Note Purchase Agreement, dated June ____, 2017 (the “Debt Purchase Agreement”).


 


1.
Number & Class of Warrant Shares; Exercise Price & Period.


 


(a)
Number of Warrant Shares; Exercise Price. The Holder will be entitled to purchase up to [insert number of shares] Shares
(the “Warrant Shares”) at an exercise price per each Warrant Share of US$[insert exercise price] (the “Exercise
Price”):


 


(b)
Vesting. The Warrant Shares shall be fully vested upon the Date of Issuance, set forth above.


 


(c)
Exercise Period. This Warrant (and all rights of the Holder hereunder) will expire and will no longer be exercisable upon the
earlier to occur of: (i) the lapse of 5 (five) years from the Closing of the Debt Purchase Agreement (as such term is defined therein),
(ii) immediately prior to the closing of a Corporate Transaction or (iii) immediately prior to the closing of an IPO (the “Expiry
Date”); provided that in the case of clause (ii) and (iii), the Company shall notify the Holder of such event by providing
the Holder a written notice by no later than fifteen (15) days prior to the closing of an IPO or Corporate Transaction, as applicable.


 


(d)
Adjustment. If the outstanding shares of the class or series of shares issuable upon exercise hereof shall be subdivided into
a greater number of shares, the Exercise Price in effect immediately prior to such subdivision shall simultaneously with the effectiveness
of such subdivision, be proportionately reduced. If the outstanding shares of the class or series of shares issuable upon exercise hereof
shall be combined into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall, simultaneously
with the effectiveness of such combination, be proportionately increased. When any adjustment is required to be made in the Exercise
Price, in accordance herewith, the number of Warrant Shares purchasable upon the exercise of this Warrant shall be changed to the number
determined by dividing (i) an amount equal to the number of Warrant Shares issuable upon the exercise of this Warrant immediately prior
to such adjustment, multiplied by the Exercise Price in effect immediately prior to such adjustment, by (ii) the Exercise Price in effect
immediately after such adjustment. In case at any time or from time to time on or after the date hereof the holders of the class of shares
of which the Warrant Shares are a part, shall have received or, on or after the record date fixed for the determination of eligible shareholders,
shall have become entitled to receive, without payment therefor, other or additional securities of the Company by way of dividend, bonus
shares or other distribution, then, and in each case, the Holder shall, upon the exercise of this Warrant, be entitled to receive, in
addition to the number of Warrant Shares receivable thereupon, and without payment of any additional consideration therefor, the amount
of such other or additional securities of the Company which such Holder would be entitled to receive had it been the holder of record
of such Warrant Shares on the date hereof and had thereafter, during the period from the date hereof to and including the date of such
exercise, retained such shares and/or all other additional shares receivable by it as aforesaid during such period.


 




    	-29-



    	 



    

 


(e)
For the purpose of this Warrant, the following terms are defined as follows:


 


“IPO”
means an initial underwritten public offering of the Shares of the Company pursuant to an effective registration statement under the
United States Securities Act of 1933, as amended or the Israeli Securities Law, 5728-1968, as amended or equivalent law of another jurisdiction


 


“Corporate
Transaction” means the consummation of any of the following transactions or series of related transactions to which the Company
is a party: (i) A merger, acquisition, reorganization or consolidation in which the Company is not the surviving entity (or survives
only as a subsidiary of another entity whose shareowners did not own all or substantially all of the shares in substantially the same
proportions as immediately prior to such transaction), except for a transaction the principal purpose of which is to change the jurisdiction
in which the Company is incorporated; or (ii) the sale, transfer, exchange or other disposition of all or substantially all of the shares
or assets of the Company (including, intellectual property rights which, in the aggregate, constitute substantially all of the Company’s
material assets), in a transaction not covered by the exception to clause (i) above; provided, however, that a bona fide
private equity financing of the Company, which does not fall under Section (i) or (ii) above, shall not constitute a Corporate Transaction
hereunder.


 


2.
Method of Exercise; Payment; Redemption.


 


(a)
Prior to the Expiry Date, this Warrant may be exercised by the Holder, in whole or in part), by the surrender of this Warrant, with a
duly executed notice of exercise in the form attached hereto as Exhibit A (the “Notice of Exercise”)
at the principal office of the Company, accompanied by the payment to the Company, by cash, wire transfer or such other method acceptable
to the Company, of an amount equal to the applicable Exercise Price under Section 1(a) above.


 


(b)
In the event that the Holder does not provide the Company with the Notice of Exercise and effect the payment in consideration for the
Warrant Shares purchased by such Holder prior to the Expiry Date, then such Holder shall be deemed to have waived its rights under this
Warrant.


 


(d)
The exercise of this Warrant shall be deemed to have been effected immediately prior to the close of business on the day on which this
Warrant is surrendered to the Company as provided in Section 2(a) above, and the Holder shall be deemed the holder of record of the Warrant
Shares as of such date.


 


(e)
In the event of any exercise of this Warrant in accordance with the terms hereof, the Company shall (i) issue the Warrant Shares to the
Holder; (ii) deliver to the Holder share certificate(s) evidencing the Warrant Shares (iii) register the Holder in its register of shareholders;
and (iv) notify the Israeli Companies Registrar of such issuance. In the event of a partial exercise of this Warrant, the Company shall
concurrently issue to the Holder a replacement warrant on the same terms and conditions of this Warrant, which shall be dated as of the
date hereof, covering the number of Warrant Shares in respect of which this Warrant shall not have been exercised.


 




    	-30-



    	 



    

 


2A.
Net Issue Exercise.


 


(a)
Notwithstanding the foregoing, in lieu of payment of the Exercise Price per Warrant Share as set forth in Section 2(a) above, the Holder
may elect to receive, for no additional consideration, Warrant Shares equal to the value of this Warrant, or any portion of the Warrant
which the Holder requests to exercise, by surrender of this Warrant at the principal office of the Company together with executed Notice
of Exercise reflecting such election, in which event the Company shall issue to the Holder a number of Warrant Shares computed using
the following formula:


 


Y
(A-B)


X
= ———————


A


 


	Where:	 	X	 	=	 	the
    number of Warrant Shares to be issued to the Holder.
	 	 	 	 	 	 	 
	 	 	Y	 	=	 	the
    number of Warrant Shares underlying the portion of this Warrant which the Holder requests to exercise pursuant to this Section
    2A.
	 	 	 	 	 	 	 
	 	 	A	 	=	 	the
    per share Fair Market Value (as defined below) of a Warrant Share as of the date of exercise pursuant to this Section 2A.
	 	 	 	 	 	 	 
	 	 	B	 	=	 	The
    per shares Exercise Price of a Warrant Share issuable under this Warrant, as in effect on the date of exercise pursuant to this Section
    2A.


 


(i)
In no event shall a Net Issue Exercise be settled in cash.


 


For
example, if the Holder elects to exercise this Warrant pursuant to this Section 2A, with respect to 10,000 Warrant Shares
(i.e. Y=10,000), and assuming that the per share Fair Market Value of a Warrant Share as of the exercise date is US$80 (i.e.
A=80), and the per share Exercise Price of a Warrant Share as of the exercise date is US$40.5359 (i.e. B=40.5359), then the
Company shall issue to the Holder 4,933 Warrant Shares upon such exercise (i.e. X=4,933).


 


(b)
Fair Market Value. For purposes of this Section 2A, the per share “Fair Market Value” of the Warrant Shares shall
mean:


 


(i)
If the Company’s Ordinary Shares are publicly traded and listed on a stock exchange, the per share Fair Market Value of the Warrant
Shares shall be the average of the closing prices of the Ordinary Shares as quoted on the principal exchange on which the Ordinary Shares
are listed, in each case for the 15 (fifteen) trading days ending five trading days prior to the date of exercise pursuant to this Section
2A, multiplied by the number of Ordinary Shares into which each Warrant Share is then convertible;


 


(ii)
If the Ordinary Shares are not publicly traded and:


 


(1)
the exercise date is immediately prior to the closing of an IPO, then the Fair Market Value shall be offer price of the IPO for each
Ordinary Share of the Company, multiplied by the number of Ordinary Shares into which each Warrant Share is then convertible,
with the exercise of Warrant and issuance of the Warrant Shares shall be deemed to have taken place immediately prior to the closing
of the IPO.


 


(2)
the exercise date is immediately prior to the closing of a Corporate Transaction, then the per share Fair Market Value of the Warrant
Shares shall the price per Warrant Share as determined as part of such Corporate Transaction.


 


(3)
otherwise, as shall be determined in good faith by the Company’s Board of Directors (the “Board”) and described
in a written notice delivered by the Company to the Holder within five (5) days following the date of exercise pursuant to this Section
2A (the “Fair Market Value Notice”); provided, however, that the Holder shall be entitled to object to such determination
by delivering a written notice to the Company to that effect (an “Objection Notice”), in which event the Fair Market
Value shall be determined by an independent appraiser selected by the Company and the Holder, whose costs of engagement shall be borne
by the Holder If an Objection Notice is not delivered by the Holder to the Company within twenty (20) days after delivery by the Company
of the Fair Market Value Notice to the Holder, such failure to so object will be deemed an irrevocable waiver and release by the Holder
of the Company, its shareholders, officers, directors, employees, representatives, legal counsel and affiliated entities, from all claims,
demands, liabilities, damages, losses, costs and expenses in connection with the determination of the Fair Market Value by the Board.


 




    	-31-



    	 



    

 


3.
Shares Fully Paid; Reservation of Shares. All of the Warrant Shares issuable upon the exercise of this Warrant will, upon
issuance and receipt of the Exercise Price therefore, be validly issues, fully paid and non-assessable, and free from all liens, charges,
claims, encumbrances, preemptive rights, rights of first refusal or similar rights, or any other third party rights with respect thereto.
At all times prior to the Expiry Date, the Company will have authorized and reserved for issuance sufficient shares, free from pre-emptive
rights to provide for the exercise of this Warrant, so that this Warrant may be exercised without additional authorization of share capital.
The Company will not by amendment of its Articles of Association or through any reorganization, transfer of assets, consolidation, merger,
dissolution, issuance or sale of its securities or any other action, avoid, or seek to avoid, the observance or performance of any of
the terms to be observed or performed hereunder, but will at all times in good faith assist in the carrying out of all provisions hereof
and in taking of all such actions as may be necessary or appropriate in order to protect the rights of the Holder hereunder against any
impairment.


 


4.
Lock-Up. In the event of an IPO, the Warrant Holder agrees that the Warrant Shares shall be subject to a “lock-up”
period on the same terms and conditions as shall be applicable to other shareholders of the Company.


 


5.
Fractional Shares. No fractional shares will be issued in connection with any exercise of this Warrant. In the event of
fractional shares, the Company will round up the number of Warrant Shares issuable upon such exercise to the nearest whole share (with
one-half being rounded upward).


 


6.
No Public Market in Shares. The Holder acknowledges that no public market now exists for any of the Warrant Shares and
that the Company has made no assurances that a public market will ever exist for the Company’s shares. The Holder further acknowledges
that it is an experienced investor and that it is fully capable of assessing the risks of exercising the Warrant Shares and of bearing
the economic risks of doing so.


 


8.
No Transferability. Neither party may assign, convey or transfer any of its rights or obligations under this Warrant; provided,
that the Holder may assign this Warrant and its rights hereunder to any of its Affiliates (as such term is defined in the Debt Purchase
Agreement).


 


9.
No Rights of Shareholders. Except as otherwise provided in the Debt Purchase Agreement, this Warrant, does not, by itself,
entitle the Holder to any rights (voting or otherwise) as a shareholder of the Company. In the absence of affirmative action by the Holder
to acquire Warrant Shares by exercise of this Warrant, no provisions of this Warrant shall cause the Holder to be a shareholder of the
Company for any purpose.


 


11.
Loss, Theft, Destruction or Mutilation of Warrant. If this Warrant is lost, stolen, destroyed or mutilated, the Company
will execute and deliver to the Holder a replacement warrant of like date, tenor, and denomination upon receipt by the Company of (a)
evidence satisfactory to the Company of the occurrence of such event; and (b) (i) in the event of mutilation, upon surrender and cancellation
of this Warrant; or (ii) in the event of loss, theft, or destruction of this Warrant, of indemnity reasonably satisfactory to the Company.


 


12.
Taxes. Each party acknowledges and agrees that any and all tax imposed on such party in connection with this Warrant,
including with relation to the grant hereof, the exercise of the Warrant Shares, and the sale of the Warrant Shares shall be borne solely
by such party, and such party will be solely liable for all such tax.


 


13.
Headings. The headings contained in this Warrant have been inserted as a matter of convenience, do not form part,
and will not affect construction of, this Warrant.


 


14.
Governing Law; Jurisdiction. This Warrant and all matters arising out of or in connection with this Warrant will be governed
by, and construed in accordance with, the laws of the State of Israel, without reference to its conflict of laws principles. Any proceeding
regarding a dispute arising under or in relation to this Agreement will be resolved exclusively in the competent courts of (i) Tel Aviv-Jaffa
if such proceeding is initiated by BioTime, and (ii) in the city of New York, New York, if such proceeding is initiated by HBL, and the
Company and the Holder hereby irrevocably submits to the sole and exclusive jurisdiction of such courts.


 


15.
Partial Invalidity. If any provision of this Warrant is held by a court of competent jurisdiction to be invalid or unenforceable
under applicable law, then such provision will be excluded from this Warrant and the remainder of this Warrant will be interpreted as
if such provision were so excluded and will be enforceable in accordance with its terms; provided, however, that in such event this Warrant
will be interpreted so as to give effect, to the greatest extent consistent with and permitted by applicable law, to the meaning and
intention of the excluded provision.


 


16.
Entire Agreement. The Debt Purchase Agreement and this Warrant constitute the entire agreement between the Holder and the
Company relating to the subject matter addressed herein, and supersedes all prior communications, contracts or agreements, whether oral
or written.


 


17.
Counterparts. This Warrant may be executed in two or more counterparts, each of which shall be deemed an original, but
all of which together shall constitute one and the same instrument. Facsimile and/or PDF signatures of a party shall be binding as evidence
of such party’s agreement hereto and acceptance hereof.


 


[Signature
Page to Follow]


 




    	-32-



    	 



    

 


IN
WITNESS WHEREOF, the parties have executed this Warrant as of the date above written.


 


	Cell Cure Neurosciences Ltd.	 
	 	 
	By:		 
	 	Dr. Charles Irving	 
	Title:	CEO	 


 


	 	Agreed
    and accepted:
	 	 
	 	 
	 	HBL-Hadasit
    Bio-Holdings Ltd.


 


	 	By:	 
	 	Title:	 


 




    	-33-



    	 



    

 


EXHIBIT
A


NOTICE
OF EXERCISE


 


To:


Cell
Cure Neurosciences Ltd.


Hadassah
Medical Center


POB
12000


Jerusalem,
91120


Israel


 


Attn:
Chief Executive Officer


 


1.
Pursuant to that certain Warrant to Purchase Shares of Cell Cure Neurosciences Ltd., the undersigned hereby elects:


 


[check
the box that applies]


 


	 	☐	to
    exercise the Warrant and purchase ____ Warrant Shares (as defined therein), and tenders herewith payment in full for the purchase
    price of the Warrant Shares being purchased.
	 	 	 
	 	☐	to
    exercise this Warrant with respect to ___ Warrant Shares by net exercise election pursuant to Section 2A of the Warrant.


 


2.
Please issue a certificate or certificates representing said Warrant Shares in the name of the undersigned, and record same in the Company’s
internal share registry.


 


	 	Very
    truly yours,
	 	 
	 	HBL-Hadasit
    Bio-Holdings Ltd.


 


	 	By:	 
	 	Title:	 


 




    	-34-



    	 



    

 


Schedule/Exhibit
D


 


Press
Release


 


Hadasit
Bio-Holdings (HBL) and BioTime Complete Shares Swap Transaction in Cellcure Neurosciences


 


As
part of the transaction, HBL, which owns 21% of Cellcure’s share capital, will sell its entire holdings to BioTime, Inc., In exchange,
BioTime will pay $12.75 million in Biotime shares to HBL


 


JERUSALEM,
June 19, 2017 /PRNewswire/ —


 


Hadasit
Bio-Holdings Ltd. (“HBL”) (TASE: HDST) announced that it has completed a share swap transaction with BioTime, Inc., (“BioTime”)
(TASE: BTX.TA) in their joint portfolio company Cell Cure Neurosciences (“Cell Cure”).


 


The
transaction is the first exit event to HBL since its establishment in 2006.


 


Cell
Cure is a privately held company held by HBL (approximately 21%) with the majority of the shares held by BioTime. Under the terms of
the transaction, HBL will sell its entire holdings in Cellcure to BioTime, as well as its interest in certain convertible loans provided
by HBL to Cell Cure.


 


The
consideration provided by BioTime in exchange of its Cell Cure shares and loans is approximately $12.75 million, payable by issuance
of BioTime shares to HBL at the transaction’s closing date.


 


BioTtime
committed to file with the Securities and Exchange Commission (the “SEC”) a registration statement to register the
shares issued by it to HBL as part of the transaction.


 


HBL
reserves the right to buy back up to approximately 5% of Cell Cure shares for a period of five years at a price of $40.5356 per share,
so as to benefit from future upside. In addition, If Cell Cure consummates a financing through the issuance of shares during the five
year period following closing of the transaction, BioTime committed to ensure that Cell Cure provide HBL with a warrant, to purchase
shares of the same type and class as issued in such financing, in an amount equal to 5% of the aggregate amount of Cell Cure’s
securities issued thereunder, on the same terms of the financing, exercisable during a period of five years commencing on the closing.
In the event that Cell Cure fails to issue HBL such warrant(s), BioTime will grant HBL an option to purchase shares of Cell Cure held
by it, on the same terms as those mentioned above.


 


At
the closing, the directors appointed to the Board of Directors of Cell Cure by HBL will resign and HBL will be entitled to appoint an
observer to Cell Cure’s Board of Directors.


 


HBL
expects to reflect in its 2017 financial statements an accounting revenue of approximately $ 9 million (before tax calculation) for the
transaction, subject to the completion date thereof.


 


HBL
largest shareholders are Centaurus Investment Ltd and Hadasit, the technology transfer company of the Hadassah Medical Center.


 


HBL
Chairman, Baruch Halpert, commented, “We are pleased to enter into a share swap agreement with BioTime, our partner for the past
several years. We have full confidence in BioTime’s management and its expertise in stem cells technology to succeed in commercializing
the breakthrough science of the stem cell therapy developed by Prof. Benjamin Reubinoff and Dr. Eyal Banin from Hadassah Medical Center.”


 


Mr.
Vincent Tchenguiz on behalf of Consensus Business Group (“CBG”) advising Centaurus Investment Ltd, said, “After many
years of supporting the company, we are very delighted that HBL has reached this significant milestone with the completion of this transaction.
Centaurus has identified the potential of HBL early on and we plan to continue investing in biomed companies in Israel.


 




    	-35-



    	 



    

 


Dr.
Tamar Raz, CEO of Hadasit, said, “CellCure is the perfect example of breakthrough science developed at Hadassah by Profs. Benjamin
Reubinoff and Eyal Banin from the Hadassah Medical Center, that reached advanced stages of development following a successful technology
transfer. Hadasit will remain involved with CellCure through its collaboration and licensing agreement with the Company.”


 


HBL
- Hadasit Bio-Holdings Ltd. is a holding company with holdings in life sciences companies involved in medical and biotechnological research
and development. HBL was founded and listed on the Tel Aviv Stock Exchange to allow the public to have a share in the biotechnological
field. Most of HBL portfolio companies originate in knowhow developed at the Hadassah Medical Center in Jerusalem.


 


“Centaurus
Investment Ltd (a BVI Company) is wholly owned by the trustees of a discretionary family trust, which is advised by CBG.


 


CBG,
chaired by Mr Vincent Tchenguiz, is a business group with diversified investment portfolio that includes structured financial instruments
and purchase, management and development of commercial and residential real estate properties. CBG is strategically focused on the biotech
industry but it is active also in renewable energy, infrastructures, cyber, enterprise software and digital media. To date, CBG has participated
in over $400 million of private equity, venture capital infrastructure and funds investment. CBG advises Centaurus on its investments
in Israel.


 


Hadasit
is the technology transfer company of the Hadassah Medical Center, established 100 years ago and considered one of Israel’s major
medical centers. The combination of practical experience, the ability to pinpoint medical needs and research at the forefront of science
has yielded a broad potential of ideas, innovation and developments in all aspects of medicine, including pharmaceuticals, diagnostics
and medical devices. Hadasit was founded in 1986 as a tool for commercializing medical technologies developed in the hospitals and invested
in turning ideas into existing products and services for the benefit of humanity. Hadasit cooperates with leading international companies
and research institutes as well as incubatorsand venture capital groups


 


CellCure
Neuroscience is a a biotechnological company focusing on developing cell therapy for degenerative retinal and macular diseases. CellCure’s
technology is based on human embryonic stem cells (hESC) which can be produced on a mass scale for any cell of the human body.


 


BioTime
is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what the company believes
to be the world’s premier collection of pluripotent cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based
on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader
applicability than pharmaceutical products. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics,
Inc. and OncoCyte Corporation, which BioTime founded and which, until recently, were majority-owned consolidated subsidiaries of BioTime.
BioTime also has a significant ownership interest in HBL at 14%.


 


SOURCE
Hadasit Bio-Holdings (HBL) and BioTime, Inc.


 


Contact
for media: Baruch Halpert, +44-7553-887187, bhalpert@sapircapital.com


 


©
Copyright BioTime, Inc.


 




    	-36-



    	 



    

 


EXHIBIT
E


 


THE
COMPANIES LAW, 5759-1999


 


Fourth
Amended and Restated Articles of Association of


CELL
CURE NEUROSCIENCES LTD.


 


1.
Name of the company


 


The
company’s name in English is: CELL CURE NEUROSCIENCES LTD.


 


2.
Purposes of the company


 


The
purposes of the company are to engage in any legally permitted business


 


3.
Registered Share Capital


 


The
share capital of the Company is One Hundred Thousand New Israeli Shekels (NIS 100,000), divided into Ten Million (10,000,000) Ordinary
Shares of nominal value of One Agora (NIS 0.01) each (the “Ordinary Shares”, or the “Shares”).


 


4.
Shareholder liability


 


The
liability of each shareholder for the indebtedness of the Company is limited to payment of the nominal value of the shares held by that
shareholder


 


5.
Share transfer, debenture, number of shareholders


 


5.1
The transfer of Shares requires the approval as set forth in Appendix A to these Articles.


 


5.2
Any invitation to the public to subscribe for any shares or debentures or debenture stock of the Company is hereby prohibited.


 


5.3
The number of shareholders for the time being of the company (exclusive of persons who are in the employment of the Company and of persons
who, having been formerly in the employment of the Company, were, while in such employment, and have continued after such employment
to be, shareholders of the Company) is not to exceed fifty (50).


 


5.4
Where two (2) or more persons hold one (1) or more share(s) in the company jointly, they shall be deemed to be a single shareholder.


 


6.
All other rights and obligations of the shareholders shall be as set forth in the provisions attached hereto as Appendix A.


 




    	-37-



    	 



    

 


Appendix
A


 


THE
COMPANIES LAW, 5759-1999


 


A
PRIVATE COMPANY LIMITED BY SHARES


 


Fourth
Amended and Restated Articles of Association of


 


CELL
CURE NEUROSCIENCES LTD.


 


The
name of the Company is: סל קיור נוירוסאיינסס
בע”מ


 


and
in English is:CELL CURE NEUROSCIENCES LTD.


 


PRELIMINARY


 


1.
The purposes of the Company are to engage in any business, commercial, industrial or other activity of any kind which is not legally
prohibited or restricted by applicable law.


 


2.
Any Article in these Articles of Association which provides for an arrangement which differs in whole or in part from any provision in
the Companies Law, 5759-1999 (the “Companies Law”) or the Companies Ordinance [New Version] 5743 - 1983 (the “Companies
Ordinance”), as the case may be, which can be stipulated against, amended or added to, in whole or with regard to specific
matters or within specific limitations, in accordance with any law, shall be considered a stipulation against the provision of the Companies
Law or Companies Ordinance, as the case may be, even if the actual stipulation is not specified in the said Article, and even if it is
expressly stated in the Article (in whatever form) that the effectiveness of the Article is subject to the provisions of any law.


 


3.
In the event of a contradiction between any Article and the provisions of any law that may not be stipulated against, amended or added
to, the provisions of the said law shall prevail, provided that the remaining Articles of these Articles of Association shall remain
in full force and effect. The invalid Article shall be replaced by a valid Article that generally comes closest to the intention of the
invalid Article.


 


4.
In interpreting any Article or examining its effectiveness, the interpretation shall be given to that Article which is most likely to
achieve its purpose as appearing therefrom or as appearing from the other Articles included within these Articles of Association.


 


Interpretation


 


5.
In these Articles, unless the context otherwise requires:


 


	Affiliate	means
    an entity or person, which, directly or indirectly through one or more intermediaries, controls, is controlled by or is under common
    control with such transferor-shareholder. For the purpose of these Articles, “Control” shall mean with respect
    to any entity, ownership as used with respect to any person means ownership (directly or indirectly) of at least fifty-one percent
    (51%) of the outstanding voting securities of a corporation or a comparable equity interest in a corporation (or such lesser percentage,
    being the maximum percentage of ownership allowed by law in a particular jurisdiction). The term “Controlled”
    shall have a correlative meaning.
	Articles	means
    these Fourth Amended and Restated Articles of Association of the Company, as they may be amended and replaced from time to time.
	BioTime	means
    BioTime Inc.
	BioTime
    Group	means
    together both BioTime and ESI.


 




    	-38-



    	 



    

 


	Board	means
    the Board of Directors of the Company, constituted in accordance with the provisions of these Articles.
	Companies
    Law	means
    the Companies Law, 5759-1999 or any successor law, as shall be in force from time to time.
	Company	means
    Cell Cure Neurosciences Ltd.
	Debt
    and Note Purchase Agreement	means
    that certain Debt and Note Purchase Agreement entered into by and between BioTime, Inc. and HBL , dated June __, 2017.
	Director	means
    a member of the Board who has been appointed in accordance with the provisions of these Articles.
	Disposition	means
    any sale, assignment, transfer or pledge of, or any charge or other encumbrance over, or any other disposition or the grant in any
    way to a third party of any other rights in shares of the Company (and “dispose” shall have the correlative meaning).
	Distribution	means
    a distribution of a dividend in cash or in kind to the Shareholders.
	Effective
    Date	means
    the date these Articles were approved by the shareholders.
	Eligible
    Shareholder	Each
    holder of Ordinary Shares who holds at least ten percent (10%) of the Company’s issued and outstanding shares capital.
	Encumber	means
    creating or allowing to exist or agreeing to create or agreeing to allow to exist any mortgage, charge (fixed or floating), pledge,
    lien, option, right to acquire, assignment by way of security, trust arrangement for the purpose of providing security or any other
    security interest of any kind, including retention arrangements.
	ESI	means
    ES Cell International Pte. Ltd.
	HBL	HBL
    – Hadasit Bio-Holdings Ltd. and/or its Affiliates
	IPO	means
    the consummation of the initial underwritten public offering of the Company’s securities pursuant to an effective registration
    statement under the Securities Act of 1933, as amended, or any equivalent law of another jurisdiction.
	New
    Securities	shall
    mean any Shares of any kind of the Company, whether now or hereafter authorized, and rights, options, or warrants to purchase said
    Shares, and securities of any type whatsoever that are, or may become, convertible into or exchangeable for said Shares; provided,
    however, that “New Securities” shall not include (i) Shares issued by the Company in connection with subdivisions,
    combinations or issuances of dividends payable in additional shares of Shares, or other securities or rights convertible into, or
    entitling the holder thereof to receive directly or indirectly, additional shares of said Shares; (ii) Shares issued to employees,
    directors or bona fide service providers of the Company pursuant to the exercise of any option plan approved by the Board; (iii)
    Ordinary Shares issued upon conversion of any preferred shares; (iv) Issuance of Ordinary Shares issued pursuant to an IPO; (v) grant
    of any warrant approved by the Board and the Shares issued to the holder of such warrant upon exercise thereof, including, but not
    limited to, any warrants granted and/or to be granted to HBL under the Debt and Note Purchase Agreement and Shares to be issued to
    HBL upon the exercise thereof; (vi) Shares issued upon conversion of the Zak Loans (as defined in the Debt and Note Purchase Agreement;
    and (vii) issuance of securities issued in connection with the acquisition of another corporation, business entity or line of business
    of another business entity by the Company by merger, consolidation, purchase of all or substantially all of the assets and/or shares,
    or other reorganization as a result of which the Company or its shareholders own more than fifty percent (50%) of the voting power
    of such corporation, which acquisition has been approved by a majority of the Board


 




    	-39-



    	 



    

 


	Ordinary
    Shares	means
    Ordinary Shares of the Company, par value NIS 0.01 each.
	Register	means
    the register of Shareholders to be maintained in accordance with the Companies Law, or, if the Company shall have any additional
    register(s) outside of Israel, any such additional register(s) as the case may be.
	Shares	means
    any shares of the Company of any class, as applicable.
	Shareholder	means
    any person registered in the Register as the owner of shares of the Company, at any given time.


 


6.
Subject to the provisions of Article 5 above, terms used but not specifically defined herein, shall have the same meaning ascribed to
such terms in the Companies Law or the Companies Ordinance, as the case may be, unless the subject or the context otherwise requires.


 


7.
The Article headings contained herein are for convenience of reference only and shall not in any way affect the meaning or interpretation
of these Articles.


 


LIMITATION
OF LIABILITY; PRIVATE COMPANY


 


8.
(a) The Company is a company limited by shares. The liability of the each shareholder for the indebtedness of the Company is limited
to payment of the nominal value of the shares held by that shareholder.


 


(b)
The Company is a private company and:


 


(1)
The number of shareholders for the time being of the Company (exclusive of persons who are in the employment of the Company and of persons
who, having been formerly in the employment of the Company, were, while in such employment, and have continued after such employment
to be, shareholders of the Company) is not to exceed fifty (50), but where two (2) or more persons hold one (1) or more share(s) in the
Company jointly, they shall, for the purposes of this Article 8, be deemed to be a single shareholder;


 


(2)
Any invitation to the public to subscribe for any shares or debentures or debenture stock of the Company is hereby prohibited; and


 


(3)
The right to transfer shares shall be restricted as hereinafter provided.


 


SHARE
CAPITAL


 


9.
The share capital of the Company is One Hundred Thousand New Israeli Shekels (NIS 100,000), divided into Ten Million (10,000,000) Ordinary
Shares of nominal value of One Agora (NIS 0.01) each (the “Ordinary Shares”, or the “Shares”).


 


RIGHTS
OF THE ORDINARY SHARES


 


10.
The Ordinary Shares shall have equal rights including voting rights and rights to dividends. The Ordinary Shares shall confer on their
holders the right to receive notices of and to attend and to vote at general meetings of the Company. They shall confer upon the holders
thereof equal rights to receive dividends and to receive, upon the Company’s winding-up, a sum equal to their nominal value, and
if a surplus remains, to receive such surplus in proportion to the nominal value of the shares held by them respectively and in respect
of which such Distribution is being made and to receive a portion of the Company’s profits, when distributed, in proportion to
the nominal value of the shares held by them, respectively, and in respect of which such distribution is being made.


 




    	-40-



    	 



    

 


SHARES


 


11.
Subject to the provisions of Article 14 below, the shares of the Company shall be under the control of the Board who may issue or allot
them or give any person the option to acquire them or otherwise dispose of them for cash or other consideration to such persons, on such
terms and conditions, and either at a premium or at par, or, subject to the provisions of the Companies Law, at a discount and at such
times as the Board may deem fit, and with full authority to serve on any person a call on any shares either at par or at a premium, or,
subject as aforesaid, at a discount, during such time and for such consideration as the Board may deem fit.


 


12.
Save as herein otherwise provided, the Company shall be entitled to treat the registered holder of any share as the absolute owner thereof,
and, accordingly, shall not, except as ordered by a court of competent jurisdiction, or as by statute required, be bound to recognize
any equitable or other claim to or interest in such share on the part of any other person and the Company shall not be bound by or required
to recognize any equitable, contingent, future or partial interest in any shares or any right whatsoever in respect of any shares other
than an absolute right to the entirety thereof in the registered holder.


 


13.
The Company may, subject to the provisions of the Companies Law, issue redeemable shares and redeem them.


 


PRE-EMPTIVE
RIGHTS


 


14.
The right to participate in the allocation of shares will be as follows:


 


14.1
Until an IPO, each Eligible Shareholder shall have the pre-emptive right to purchase, its pro-rata portion, or any part thereof, of any
New Securities that the Company may, from time to time, propose to sell and issue.


 


14.2
The Eligible Shareholder’s pro-rata portion shall be the ratio of the number of shares of the Company then held by such Eligible
Shareholder as of the date of the Rights Notice (as defined below), to the aggregate number of shares (on an as-converted basis) held
by all Shareholders as of such date.


 


14.3
Each Eligible Shareholder shall be also entitled to purchase any New Securities that are not purchased by the other Eligible Shareholders,
by indicating such intent in his response notice to the Company as set forth below, provided, however, that if such over-subscriptions
exceed the total number of New Securities available for sale and issue by the Company in such instance, then the over-subscriptions shall
be cut back in accordance with each Eligible Shareholder’s pro-rata portion calculated based on ratio of the number of shares of
the Company held by such Eligible Shareholder as of the date of the Rights Notice, to the aggregate number of shares held by all other
Eligible Shareholders entitled to and who have indicated their intent to participate in the over-allotment as aforesaid, as of such date.


 


14.4
If the Company proposes to issue New Securities, it shall deliver to the Eligible Shareholders written notice thereof (the “Rights
Notice”), describing the New Securities, the price, the general terms upon which the Company proposes to issue them, and the
number of shares that the Eligible Shareholder has the right to purchase under this Article. Each Eligible Shareholder shall then be
entitled to notify the Company, by written notice received by the Company within ten (10) days after receipt of the Rights Notice by
such Eligible Shareholder, of the number of New Securities it wishes to purchase or obtain, at the price and on the terms specified in
the Rights Notice.


 


14.5
If any Eligible Shareholder fails to provide the Company its notice as aforesaid within the described ten (10) day period, then such
Eligible Shareholder shall be deemed to have waived its pre-emptive right pursuant to this Article 14 in relation to the applicable Rights
Notice.


 




    	-41-



    	 



    

 



14.6
                                            If the Eligible Shareholders fail to exercise in full their pre-emptive rights within the
                                            period or periods specified in this Article, the Company shall have ninety (90) days after
                                            delivery of the Rights Notice to sell the New Securities the Eligible Shareholders do not
                                            elect to purchase at a price and upon general terms no more favorable to the purchasers thereof
                                            than specified in the Rights Notice. If the Company has not sold the New Securities within
                                            said ninety (90) day period, the Company shall not thereafter issue or sell any New Shares
                                            without first offering such securities to the Eligible Shareholders in the manner provided
                                            above.


 


TRANSFER
OF SHARES


 


15.
Any transfer, assignment, pledge, mortgage or other Disposition by a shareholder of all or part of its Shares in the Company (each, a
“Transfer”) shall be subject to the prior approval of the Board, and no Transfer shall have any legal effect without
such approval. Furthermore, any Transfer of Shares of the Company shall be made in accordance with the provisions of these Articles and
any applicable law.


 


16.
No shareholder shall Encumber any of its Shares.


 


17.
Notwithstanding any other provision or article in these Articles, a Shareholder shall not be entitled to Transfer its Shares in the Company
and/or its rights and obligations under these Articles to a person or entity which competes, directly or indirectly, with the business
of the Company, without the prior written consent of the other Shareholders.


 


18.
No Transfer shall be approved or registered unless a proper instrument of transfer has been submitted to the Company (or its transfer
agent) together with the share certificate for the transferred shares (if such has been issued) and with any other evidence the Board
may require in order to prove to its satisfaction the rights of the transferor in the transferred shares.


 


The
instrument of transfer shall be signed by the transferor and the transferee, shall be duly stamped, if required by law, and the transferor
shall be considered the owner of the shares until the transferee is registered in the Register in respect of the shares transferred to
him. The Board may decide that the signature of a witness on the instrument of transfer is not necessary. The instrument of transfer
of any share shall be in writing in the following form or as near thereto as possible, or in a usual or accepted form that shall be approved
by the Board:


 


“I
____________ of _____________ (the “Transferor”) in consideration of the sum of _______ paid to me by __________ of _____________
(the “Transferee”) hereby transfer to the Transferee ________ shares of Cell Cure Neurosciences Ltd. of nominal value 0.01
NIS each, denoted by numbers _____ to _____ (both inclusive), to be held by the Transferee, the executors and administrators of his estate,
his custodian and his legal personal representative, under the same conditions under which I myself held them immediately prior to signing
this instrument of transfer, and I, the Transferee, hereby agree to accept the above mentioned shares in accordance with the above mentioned
conditions.


 


In
witness whereof we hereby affix our signatures this ______ day of ____________, 2___.


 


	 	 	 	 	 
	 	The
    Transferor	 	The
    Transferee	 
	 	 	 	 	 
	 	Witness
    to the signature of the Transferor	 	Witness
    to the signature of the Transferee	 


 


 


The
Company may impose a fee for registration of a share transfer, at a reasonable rate as may be determined by the Board from time to time.


 


19.
Instruments of transfer that are registered shall remain in the Company’s possession; however, instruments of transfer which the
Board refuses to register in accordance with the provisions of these Articles of Association, shall be returned, on demand, to whomever
delivered them along with the share certificate (if delivered).


 




    	-42-



    	 



    

 


RIGHT
OF FIRST REFUSAL; CO-SALE


 


20.
Until an IPO, each Eligible Shareholder shall have a right of first refusal with respect to any Transfer of all or any Shares by any
Shareholder (“Offeree”), according to the following provisions:


 


20.1
Any shareholder, proposing to transfer all or any of its Shares and/or other securities (if any), (the “Offered Shares”),
pursuant to the terms of a bona fide offer received from any person or entity, except to an Affiliate (the “Offeror) shall
first request the Company, by written notice (which shall contain all the information necessary to enable the Company to do so), to offer
the Offered Shares, on the terms of the proposed transfer, to all the Eligible Shareholders. The Company shall comply with such request
by sending the Eligible Shareholders a written notice (the “Offer” and the “Offer Notice”), stating
therein the identity of the Offeror and of the proposed transferee(s) and the proposed terms of sale of the Offered Shares. Any Eligible
Shareholder may accept such Offer in respect of all or any of the Offered Shares by giving the Company notice to that effect within ten
(10) days after being served with the Offer Notice (the “Notice Period”).


 


20.2
If the acceptances, in the aggregate, are in respect of all of, or more than, the Offered Shares, then the accepting Eligible Shareholders
shall acquire the Offered Shares, on the terms aforementioned, in proportion to their respective holdings, provided, that no Eligible
Shareholder shall be entitled to acquire under the provisions of this Article 20 more than the number of Offered Shares initially accepted
by such Eligible Shareholders, and upon the allocation to it of the full number of shares so accepted, it shall be disregarded in any
subsequent computations and allocations hereunder and provided further that each Eligible Shareholder shall be entitled to purchase the
pro rata portion of any other Eligible Shareholder that does not exercise its rights pursuant to this Article 20. Any Offered Shares
remaining after the computation of such respective entitlements shall be re-allocated among the accepting Eligible Shareholders (other
than those to be disregarded as aforesaid), in the same manner, until one hundred percent (100%) of the Offered Shares have been allocated
as aforesaid.


 


20.3
If the acceptances, in the aggregate, are in respect of less than the number of Offered Shares, then the Offeror, at the expiration of
the Notice Period, shall be entitled to Transfer all (and not part) of the remaining Offered Shares to the proposed transferee(s) identified
in the Offer Notice, provided, however, that in no event shall the Offeror Transfer any of the Offered Shares to any transferee
other than such accepting Eligible Shareholders or such proposed transferee(s) or transfer the same on terms more favorable to the buyer(s)
than those stated in the Offer Notice, and, provided, further, that if the remaining amount of Offered Shares are not transferred within
ninety (90) days after the expiration of the Notice Period, then any transfer of the Offered Shares shall again be subject to the provisions
of this Article 20.


 


20.4
For the purposes of any Offer under this Article 20, the respective holdings of any number of accepting Eligible Shareholders shall mean
the respective proportions of the aggregate number of Ordinary Shares held by such accepting Eligible Shareholders as determined prior
to such Offer Notice.


 


20.5
The restrictions set forth in this Article 20 shall not apply in connection with the sale of all or substantially all of the Company’s
issued and outstanding share capital and will terminate upon the closing of an IPO.


 


20.6
Subject to Article 17 above, the provisions of this Article 20 shall not apply to any Transfer to an Affiliate.


 


20.7
The restrictions set forth in Article 20 above shall not apply upon the transfer of Shares from BioTime to HBL upon the exercise of any
BioTime Call Option, as defined in the Debt and Note Purchase Agreement and in accordance with the terms therein.


 


21.
Co-Sale


 


21.1
Upon receipt of the Offer Notice (in accordance with Article 20 above), each Eligible Shareholder shall in lieu of his right to purchase
the Offered Shares, have the option, exercisable by written notice to the Offeree, within the Notice Period, to require the Offeree to
provide as part of its proposed Transfer that such Eligible Shareholder be given the right to participate in the Transfer and to Transfer
up to such amount of shares in the Company owned by such Eligible Shareholder determined by multiplying the total number of shares being
Transferred by a fraction, the numerator of which is the number of issued and outstanding shares held by such Eligible Shareholder and
the denominator of which is the total number of issued and outstanding shares held by all of the Eligible Shareholders and the Offeree
(the “Pro Rata Share”), by including the Pro Rata Share held by such Eligible Shareholder in the shares being Transferred
to any proposed purchaser thereof. The Transfer by any such Eligible Shareholder in accordance with this Article 21 shall be on the same
terms and conditions under which the securities of the Offeree are being Transferred.


 




    	-43-



    	 



    

 


21.2
In the event that Eligible Shareholders choose to exercise their rights hereunder (“Exercising Entitled Shareholders”),
the Offeree must reduce the number of shares it desires to Transfer from the total amount of shares to be purchased by the Offeror and
the Exercising Entitled Shareholders will contribute all of their Pro Rata Shares and the Offeree will contribute the remaining number
of shares up to the total number of shares to be purchased by the Offeror.


 


21.3
It is hereby clarified that: (i) the co-sale right stated in this Article 21 does not derogate from the right of first refusal under
Article 20 above, and (ii) a Transfer shall be subject to the co-sale right only if the right of first refusal set forth in Article 20
above is not exercised.


 


22.
The restrictions set forth in Article 21 above shall not apply in connection with the sale of all or substantially all of the Company’s
issued and outstanding share capital and will terminate upon the closing of an IPO.


 


SHARE
CERTIFICATES


 


23.
The certificates of title to shares (“Share Certificates”) shall be issued under the seal or the rubber stamp of the
Company or its printed name and shall bear the signature of one (1) Director or such other person or persons as are authorized by the
Board.


 


24.
Every Shareholder shall be entitled to receive one Share Certificate for all the shares of a particular class registered in his name,
and if the Board so approves (upon payment of the amount which may from time to time be fixed by the Board), to several Share Certificates
each for one or more such shares.


 


25.
A Share Certificate, registered in the names of two or more persons shall be delivered to the person first named on the Register in respect
of such co-ownership.


 


26.
If a Share Certificate is defaced, lost or destroyed, it may be renewed on payment of such fee, if any, and on such terms as to evidence
and indemnity, as determined by the Board.


 


CALLS


 


27.
The Board may, from time to time, make such calls as it deems fit upon the Shareholders in respect of all moneys unpaid on the shares
held by them respectively, and by the conditions of allotment thereof not made payable at fixed times or on fixed terms, and each Shareholder
shall pay the amount of every call so made on him to the persons and at the time and place appointed by the Board. A call may be made
payable by installments, and shall be deemed to have been made when the resolution of the Board authorizing such call was passed.


 


28.
At least fourteen (14) days’ notice of any call shall be given, specifying the time and place of payment, and to whom such call
shall be paid, provided that before the time for payment of such call the Board may, by notice in writing to the Shareholders, revoke
the same or extend the time for payment thereof.


 


29.
The joint holders of a share shall be jointly and severally liable to pay all calls in respect thereof.


 


30.
If, by the terms of issue of any share or otherwise any amount is made payable at any fixed time or on any fixed term or by installments
at fixed times or on fixed terms, whether on account of the nominal value of the share or by the way of premium, every such amount or
installment shall be payable as if it were a call duly made by the Board of which due notice had been given, and all the provisions herein
contained in respect of such calls shall apply to such amount or to such installment.


 




    	-44-



    	 



    

 


31.
If the amount of any call or installment is not paid on or before the due date for payment thereof, then the person who is the then owner
of the share on which the call was made or the installment became due, shall pay interest on the said amount at the maximum rate permissible
under law for the time being, or at such lesser rate as may be fixed by the Board from time to time, as from the date of payment until
the same is actually paid. The Board shall, however, be at liberty to waive the payment of interest, wholly or in part. No Shareholder
shall be entitled to receive any dividend or to exercise any privileges as a Shareholder with respect to shares not fully paid for until
he shall have paid all calls for the time being due and payable on every share held by him whether alone or jointly with any other person
together with interest and expenses (if any).


 


32.
If the Board so determines, it may receive from any Shareholder willing to advance the same, any amounts due on account of all or any
of his shares which have not yet been called or in respect of which the date of payment has not yet occurred, and, unless otherwise agreed
with such Shareholder, the Board may pay him interest on all or any of the amounts so advanced, up to the date when said amounts would,
if not paid in advance, have fallen due, at such rate of interest as may be agreed upon between the Board and such Shareholder, and the
Board may at any time repay any amount so advanced by giving such Shareholder seven (7) days’ prior notice in writing.


 


33.
The Board may differentiate between Shareholders in relation to the amount of any call and to the date of payment.


 


34.
For the purpose of the provisions relating to calls, forfeiture and lien, reference is made herein to moneys and/or amounts payable shall
also be construed as agreed services in-kind unperformed or to be performed.


 


TRANSMISSION
OF SHARES


 


35.
The Company may recognize the receiver or liquidator of any shareholder in winding-up or dissolution, or the trustee in bankruptcy or
any official receiver of a bankrupt shareholder as being entitled to the shares registered in the name of such shareholder.


 


36.
The receiver or liquidator of a shareholder in winding-up or dissolution, or the trustee in bankruptcy, or any official receiver of any
bankrupt shareholder, upon producing such evidence as the Board may deem sufficient that he sustains the character in respect of which
he proposes to act under this Article or of his title, may, with the consent of the Board (which the Board may grant or refuse in its
absolute discretion), be registered as a shareholder in respect of such shares, or may, subject to the regulations as to transfer herein
contained, transfer such shares.


 


37.
A person upon whom the ownership of a share devolves by transmission shall be entitled to receive, and may give a discharge for any dividends
or other monies payable in respect of the share but he shall not be entitled in respect of it to receive notices, or to attend or vote
at meetings of the Company, or, save as otherwise provided herein, to exercise any of the rights or privileges of a shareholder unless
and until he shall be registered in the Register.


 


GENERAL
MEETINGS


 


38.
The Company shall not be obligated to hold an annual general meeting of its shareholders except to the extent it is necessary in order
to appoint an Auditor. All general meetings of the shareholders other than annual general meetings of the shareholders shall be called
extraordinary or special meetings of the shareholders.


 


39.
The Board may whenever it thinks fit convene an extraordinary meeting, and shall be obliged to do so upon a request in writing as provided
in the Companies Law.


 


40.
Unless a longer period is prescribed by applicable law, at least seven (7) days prior notice, specifying the place, the day and the hour
of the meeting and the general nature of every matter on the agenda, shall be given to all Shareholders entitled to receive notices by
notice sent by mail or otherwise served as hereinafter provided. Anything herein to the contrary notwithstanding, with the consent of
all Shareholders entitled to receive notices of and vote at meetings, a resolution may be proposed and passed although less than seven
(7) days’ notice or the period otherwise required by law, as the case may be, was given.


 




    	-45-



    	 



    

 


41.
The accidental omission to give notice of a meeting to any Shareholder, or the non-receipt of notice by one of the Shareholders shall
not invalidate the proceedings at any meeting.


 


42.
Subject to the provisions of the Companies Law, a meeting of the Shareholders shall be convened at such place as the Board shall direct.
If no location for the convening of the meeting is specified by the Board, the meeting shall convene at the offices of the Company.


 


PROCEEDINGS
AT GENERAL MEETINGS


 


43.
No business shall be transacted at a general meeting unless the requisite quorum is present at the commencement of the business, and
no resolution shall be passed unless the requisite quorum is present when the resolution is voted upon. One (1) (or more) shareholders,
present in person or by proxy, holding or representing shares conferring in the aggregate more than sixty percent (60%) of the voting
rights in the Company, shall constitute a quorum.


 


44.
If a quorum is not present within half an hour from the time appointed for the meeting, the meeting shall stand adjourned to the same
day in the following week, at the same time and place, unless provided otherwise in the notice, or at such time and place as the Board
may determine. If at such adjourned meeting, there is no quorum as prescribed above in Article 43 above, then Shareholders holding a
majority of the issued and outstanding Shares shall constitute the quorum.


 


45.
Unless otherwise prescribed by applicable law, a resolution of the shareholders will be deemed adopted if approved by a simple majority
of the votes of the shareholders present at the meeting, represented personally or by proxy at which a quorum is present and voting thereon.


 


46.
Shareholders entitled to be present and vote at a meeting may participate in a by any means of communication, so long as all those participating
in the meeting can hear each other simultaneously, and such participation in a meeting shall constitute attendance in person at the meeting.


 


47.
A resolution in writing signed by all shareholders then entitled to vote at general meetings or to which all such shareholders have given
their written consent (including, but not limited to, by letter, facsimile, e-mail or otherwise) shall be deemed to have been adopted
as if it were adopted at a general meeting of the Company duly convened and held. Any such resolution may consist of several documents
in like form and signed or consented to as aforesaid, by one or more shareholders.


 


48.
A shareholder may appoint a proxy to vote in his place and the proxy need not be a shareholder in the Company. The appointment of a proxy
shall be in writing signed by the person making the appointment or by an attorney authorized for this purpose, and if the person making
the appointment is a corporation, by a person or persons authorized to bind the corporation.


 


THE
BOARD OF DIRECTORS


 


49.
The number of members of the Board shall be not less than one (1) and not more than five (5) members.


 


50.
The BioTime Group shall be entitled to appoint, remove and replace five (5) members to the Board in writing to the Company. A Director
shall commence his duties or shall cease to serve as Director, as the case may be, on the date specified in the written notice to the
Company of appointment or removal from office (or in the absence of any specified date, on the date of the receipt by the Company of
such notice).


 


51.
Every Director shall hold office until he is removed in accordance with the preceding Article or the office is vacated in a manner set
forth in Article 54 below.


 




    	-46-



    	 



    

 


52.
(a) Subject to the provisions of the Companies Law, a Director shall have the right, by written notice to the Company, to appoint a person
as a substitute to act in his place (the “Alternate Director”), to remove the Alternate Director and appoint another
in his place and to appoint an Alternate Director in place of a Alternate Director whose office was vacated for any reason whatsoever.
A person who is not qualified to be appointed as a Director may not be appointed as an Alternate Director. Any Director may be appointed
as an Alternate Director.


 


(b)
Any notice given to the Company as aforesaid shall become effective on the date fixed therein or upon delivery to the Company, whichever
is later. Unless the appointing Director, by the instrument appointing an Alternate Director, limits the time or scope of the appointment,
the appointment is effective for all purposes until the appointing Director ceases to be a Director or terminates the appointment.


 


(c)
An Alternate Director shall have, subject to any instructions or limitations contained in the instrument appointing him, all the authority
and powers held by the Director for whom he acts as substitute, provided however, that he may not in turn appoint a substitute for himself
(unless the instrument appointing him otherwise expressly provides), and provided further that an Alternate Director shall have no standing
at any meeting of the Board or any committee thereof at which the Director appointing him is personally present or at which the Director
appointing him is not entitled to participate in accordance with the provisions of these Articles.


 


(d)
The office of an Alternate Director shall, ipso facto, be vacated if he is removed by the Director appointing him, or if the office of
the Director for whom he acts as substitute is vacated for any reason whatsoever, or if one of the circumstances described in sub-Articles
(a) - (e) of Article 54 should befall the Alternate Director.


 


(e)
An Alternate Director shall alone be responsible for his actions and omissions, and shall not be deemed an agent of the Director who
appointed him.


 


(f)
Every Alternate Director shall be entitled to receive, so long as he serves as a substitute, notice of meetings of the Board and of any
relevant committees.


 


53.
Subject to applicable law, a Director who has ceased to hold office shall be eligible for re-election or re-appointment.


 


54.
The office of a Director shall, ipso facto, be vacated upon the occurrence of any of the following events:


 


(a)
Upon his death, or, if the Director is a company - upon its winding-up;


 


(b)
Should he be declared to be of unsound mind;


 


(c)
Should he become bankrupt;


 


(d)
Should he resign his office by notice in writing to the Company;


 


(e)
Should he be removed from office by written notice to the Company pursuant to Article 50 above.


 


55.
A Director shall not be required to hold qualification shares.


 


56.
A Director shall not be paid remuneration out of the funds of the Company for his services as a Director unless such remuneration is
approved by a shareholders’ resolution and pursuant to the Companies Law.


 


57.
Every Director shall be entitled to be reimbursed for his reasonable travel, hotel and other expenses related to his participation in
meetings of the Board etc., and in fulfilling his office as a Director, against presentation of supporting documentation.


 


58.
For as long as the Debt Warrant (as defined in the Debt and Note Purchase Agreement) remains exercisable, and thereafter for as long
as HBL holds any Shares, HBL shall be entitled to appoint, replace and dismiss, on its behalf, one (1) observer (the “HBL Observer”)
to the Board who shall be invited to and shall have the right to attend all meetings (including meetings held by any means of communication)
of the Board in a non-voting capacity and to receive any and all notices, information, materials and proposed resolutions (including,
without limitation, any proposed resolutions for adoption in writing) delivered to the members of the Board concurrently with the delivery
thereof to the members of the Board; provided, however, that the HBL Observer may be excluded from any Board meeting or
portion thereof and need not be provided such materials if the Board reasonably determines in good faith that such exclusion of the HBL
Observer’s attendance at such meeting or access to such information is necessary in order to preserve an attorney-client privilege
or to avoid a conflict of interest between the Company and HBL.


 




    	-47-



    	 



    

 


PROCEEDINGS
OF THE BOARD OF DIRECTORS


 


59.
Any Director may, at any time, convene a meeting of the Board. Meetings of the Board shall be held in such place as determined by the
majority of the Directors.


 


60.
The quorum for a meeting of the Board and/or for any matter to be brought before the Board shall be constituted by the presence of at
least a majority if the number of Directors then appointed. If within half an hour from the time appointed for the meeting a quorum is
not present, the meeting shall disperse and reconvened at the same place forty-eight (48) hours from the time it was first convened,
and at that meeting, the present directors shall constitute a legal quorum.


 


Unless
and to the extent provided otherwise in the Companies Law, a Director who is an interested party in any transaction, shall be counted
for purposes of a quorum despite his interest.


 


A
Director may participate personally or by his Alternate Director.


 


61.
Notice of a meeting of the Board shall be sent to all Directors at their registered addresses, by facsimile, email or other reliable
method of transmission, at least forty-eight (48) hours prior to the meeting unless all Directors agree to shorter notice or waive notice
altogether.


 


62.
A meeting of the Board may be held by any means of communication, so long as all those participating in the meeting can hear each other
simultaneously. Each Director shall have one vote. All resolutions of the Board will be adopted by a simple majority of the Directors
present and voting in respect thereto.


 


63.
The Board shall elect one (1) of its members to be the Chairman of the Board, and may remove such Chairman from office and appoint another
in his place. The Chairman of the Board shall take the chair at every meeting of the Board, but if there is no such Chairman, or if at
any meeting he is not present within fifteen (15) minutes of the time appointed for the meeting, or if he is unwilling to take the chair,
the Directors present shall choose one of their number to be the Chairman of such meeting.


 


64.
The Chairman of a meeting of the Board, whether he is the Chairman of the Board or any other member of the Board, shall have no extra
or casting vote.


 


65.
A meeting of the Board at which a quorum is present shall be competent to exercise all the authorities, powers and discretions for the
time being vested in or exercisable by the Board.


 


66.
The Board may attend meetings by telephone or any other means of communication (including by means of several types of telecommunications
media, and including a manner in which part of the Directors are present in person at the place of the meeting and the remaining Directors
participate in the meeting by means of telecommunications), provided that all the Directors can hear each other simultaneously.


 


67.
A resolution in writing signed by all of the Directors then in office and lawfully entitled to vote thereon or to which all such Directors
have given their written consent (by letter, facsimile, e-mail or otherwise) shall be deemed to have been unanimously adopted by a meeting
of the Board duly convened and held.


 


68.
Any action taken by or in accordance with a decision of the Board or by a Director, acting in his capacity as Director, shall be valid
and effective even if it is subsequently discovered that there was a defect in the appointment of any of the Directors or if all or one
of them was disqualified, in each case as if each of the Directors had been lawfully elected and as if he was fully qualified to act
as Director or Alternate Director, as the case may be.


 




    	-48-



    	 



    

 


POWERS
OF THE BOARD OF DIRECTORS


 


69.
The management of the business of the Company shall be vested in the Board, and the Board may exercise all such powers and do all such
acts and things as the Company is, by its Articles or under the law, authorized to exercise and do, and are not hereby or by statute
directed or required to be exercised or done by the Company in general meeting, but subject, nevertheless, to the provisions of the Companies
Law, and to these Articles and any regulations or resolution not being inconsistent with these Articles made from time to time by the
Company in general meeting; provided that no such regulation or resolution shall invalidate any prior act done by or pursuant to the
directions of the Board which would have been valid if such regulation or resolution had not been made.


 


MINUTES
AND THE SEAL


 


70.
The Board shall cause minutes to be duly recorded regarding: the names of the Directors present at each meeting of the Board and of any
committee of the Board; the names of the shareholders present at each general meeting, and the proceedings and resolutions of general
meetings and of meetings of the Board. Any minutes of a meeting of the Board or of a general meeting of the Company, signed by the Chairman
of such meeting shall be accepted as prima facie evidence of the matters therein recorded.


 


DIVIDENDS
AND RESERVE FUND


 


71.
The Board may, from time to time, set aside, out of the profits of the Company, such sums as it thinks proper, as a reserve fund to meet
contingencies, or for equalizing dividends, or for special dividends, or for repairing, improving and maintaining any of the property
of the Company, and for such other purposes as the Board shall in its absolute discretion think conducive to the interests of the Company,
and may invest the sums so set aside in such investments as it may think fit, and from time to time deal with and vary such investments,
and dispose of all or any part thereof for the benefit of the Company, and may divide the reserve fund into such special funds as it
thinks fit, and employ the reserve fund or any part thereof in the business of the Company, and that without being bound to keep the
same separate from the other assets of the Company. The Board may also, without placing the same to reserve, carry forward any profits
that it deems prudent not to divide.


 


72.
Subject to the provisions of the Companies Law and to the extent permitted by law, the Board may from time to time declare such dividends
as may appear to the Board to be justified by the profits of the Company and cause the Company to pay such dividends. The Board shall
have the full authority to determine the time for payment of such dividends, and the record date for determining the Shareholders entitled
thereto, provided such date is not prior to the date of the resolution to distribute the dividend and no Shareholder who shall be registered
in the Register with respect to any shares after the record date so determined shall be entitled to share in any such dividend with respect
to such shares.


 


73.
Subject to these Articles, the Board may resolve that a dividend may be paid, wholly or partly, by the Distribution of specific assets,
and, in particular, by Distribution of paid-up shares, debentures or debenture stock of any other company, or in any one or more such
ways.


 


74.
No dividend shall be paid other than out of the profits of the Company, as defined in the Companies Law, and no interest shall be paid
by the Company on dividends.


 


WINDING
UP


 


75.
(a) If the Company shall be wound up, the liquidator may proportionally divide amongst the shareholders in cash the whole or any part
of the assets of the Company and may with the like sanction, vest the whole or any part of such assets in trustees upon such trusts for
the benefit of the shareholders as the liquidator with the like sanction shall think fit.


 




    	-49-



    	 



    

 


(b)
The power of sale of a liquidator shall include a power to sell wholly or partially for shares or debentures, or other obligations of
another company, either then already constituted, or about to be constituted, for the purpose of carrying out the sale.


 


INSURANCE,
INDEMNITY AND RELEASE


 


76.
Subject to the provisions of the Companies Law, the Company may indemnify its Office Holders, to the maximum extent permitted by law,
with respect to any of the following:


 


(a)
a monetary liability or expense imposed on or incurred by him in favor of a third party in any judgment, including any settlement confirmed
as judgment and an arbitrator’s award which has been confirmed by the court, in respect or as a result of an act (or omission)
performed by the Office Holder by virtue of the Office Holder being an Office Holder of the Company; or


 


(b)
reasonable litigation expenses, including legal fees, paid for by the Office Holder, or which the Office Holder is obligated to pay under
a court order, in a proceeding brought against the Office Holder by the Company, or on its behalf, or by a third party, or in a criminal
proceeding in which the Office Holder is found innocent, or in a criminal proceeding in which the Office Holder was convicted of an offense
that does not require proof of criminal intent, all in respect or as a result of an act (or omission) performed by the Office Holder
by virtue of the Office Holder being an Office Holder of the Company; or


 


(c)
reasonable litigation expenses, including legal fees, expended by him in respect or as a result of an investigation or proceeding instituted
against him by a competent authority, which investigation or proceeding has not ended in a criminal charge or in a financial liability
in lieu of a criminal proceeding, or has ended in a financial obligation in lieu of a criminal proceeding for an offence that does not
require proof of criminal intent (the phrases “proceeding that has not ended in a criminal charge” and “financial obligation
in lieu of a criminal proceeding” shall have the meaning as defined in Section 260(a)(1a) of the Companies Law).


 


The
Company may: (i) undertake to indemnify an Office Holder as aforesaid prospectively, provided that, with respect to an undertaking to
indemnify as set forth in Article 76(a) above, the undertaking to indemnify is limited to events which in the opinion of the Board can
be foreseen, in view of the Company’s then actual activities, when the undertaking to indemnify is given, and to an amount or criteria
set by the Board as reasonable under the circumstances and that the undertaking to indemnify specifies the events which in the opinion
of the Board can be foreseen, in view of the Company’s then actual activities, when the undertaking is given and also the amount
or criteria set by the Board as reasonable under the circumstances, and (ii) indemnify an Office Holder as aforesaid retroactively.


 


77.
Subject to the provisions of the Companies Law and to the maximum extent permitted by law, the Company may procure, for the benefit of
any of its Office Holders, office holders’ liability insurance for any liabilities incurred by them in respect or as a result of
any act (or omission) carried out by them as office holders of the Company by virtue of the Office Holder being an Office Holder of the
Company, with respect to any of the following:


 


(a)
a breach of the duty of care owed to the Company or any other person;


 


(b)
a breach of the fiduciary duty owed to the Company, provided that the Office Holder acted in good faith and had reasonable grounds to
assume that the action would not injure the Company; or


 


(c)
a monetary liability imposed on an Office Holder in favor of a third party.


 


78.
The Company may, to the maximum extent permitted by law, exempt and release an Office Holder, including in advance, from and against
all or part of his liability for monetary or other damages due to, arising or resulting from, a breach of his duty of care to the Company
other than a breach of his duty of care to the Company upon “distribution” as such term is defined in the Companies Law.


 


79.
The provisions of Articles 76-78 above are not intended, and shall not be interpreted, to restrict the Company in any manner in respect
of the procurement of insurance and/or in respect of indemnification (i) in connection with any person who is not an Office Holder, including,
without limitation, any employee, agent, consultant or contractor of the Company who is not an Office Holder, and/or (ii) in connection
with any Office Holder to the extent that such insurance and/or indemnification is not specifically prohibited under applicable law;
provided that the procurement of any such insurance and/or the provision of any such indemnification shall be approved by the Board and/or
otherwise as required by the Companies Law.


 


80.
In the event of any change after the date of adoption of these Articles of Association in any applicable law, statute or rule which expands
the right of an Israeli company to indemnify or insure an Office Holder, these Articles of Association shall automatically be deemed
to enable the Company to so expand the scope of indemnification and/or insurance that the Company is able to provide.


 


*****


 




    	-50-



    	 



    

 


SCHEDULE
D


 


Press
Release


 


Schedule/Exhibit
D


 


Press
Release


 


Hadasit
Bio-Holdings (HBL) and BioTime Complete Shares Swap Transaction in Cellcure Neurosciences


 


As
part of the transaction, HBL, which owns 21% of Cellcure’s share capital, will sell its entire holdings to BioTime, Inc., In exchange,
BioTime will pay $12.75 million in Biotime shares to HBL


 


JERUSALEM,
June 19, 2017 /PRNewswire/ —


 


Hadasit
Bio-Holdings Ltd. (“HBL”) (TASE: HDST) announced that it has completed a share swap transaction with BioTime, Inc., (“BioTime”)
(TASE: BTX.TA) in their joint portfolio company Cell Cure Neurosciences (“Cell Cure”).


 


The
transaction is the first
exit event to HBL since its establishment in 2006.


 


Cell
Cure is a privately held company held by HBL (approximately 21%) with the majority of the shares held by BioTime. Under the terms of
the transaction, HBL will sell its entire holdings in Cellcure to BioTime, as well as its interest in certain convertible loans provided
by HBL to Cell Cure.


 


The
consideration provided by BioTime in exchange of its Cell Cure shares and loans is approximately $12.75 million, payable by issuance
of BioTime shares to HBL at the transaction’s closing date.


 


BioTtime
committed to file
with the Securities and Exchange Commission (the “SEC”) a registration statement to register the shares issued by
it to HBL as part of the transaction.


 


HBL
reserves the right to buy back up to approximately 5% of Cell Cure shares for a period of five
years at a price of $40.5356 per share, so as to benefit from future upside. In addition, If Cell Cure consummates a financing
through the issuance of shares during the five year period following closing of the transaction,
BioTime committed to ensure that Cell Cure provide HBL with a warrant, to purchase shares of the same type and class as issued in such
financing, in an amount equal to 5% of the aggregate amount of Cell Cure’s securities
issued thereunder, on the same terms of the financing, exercisable during a period of five
years commencing on the closing. In the event that Cell Cure fails to issue HBL such warrant(s), BioTime will grant HBL an option to
purchase shares of Cell Cure held by it, on the same terms as those mentioned above.


 


At
the closing, the directors appointed to the Board of Directors of Cell Cure by HBL will resign and HBL will be entitled to appoint an
observer to Cell Cure’s Board of Directors.


 


HBL
expects to reflect in its 2017 financial
statements an accounting revenue of approximately $ 9 million (before tax calculation) for the transaction, subject to the completion
date thereof.


 


HBL
largest shareholders are Centaurus Investment Ltd and Hadasit, the technology transfer company of the Hadassah Medical Center.


 


HBL
Chairman, Baruch Halpert, commented, “We are pleased to enter into a share swap agreement with BioTime, our partner for the
past several years. We have full confidence in BioTime’s management and its expertise in stem cells technology to succeed in commercializing
the breakthrough science of the stem cell therapy developed by Prof. Benjamin Reubinoffand
Dr. Eyal Banin from Hadassah Medical Center.”


 




    	-51-



    	 



    

 


Mr.
Vincent Tchenguiz on behalf of Consensus Business Group (“CBG”) advising Centaurus Investment Ltd, said, “After
many years of supporting the company, we are very delighted that HBL has reached this significant milestone with the completion of this
transaction. Centaurus has identified the potential of HBL early on and we plan to continue investing in biomed companies in Israel.


 


Dr.
Tamar Raz, CEO of Hadasit, said, “CellCure is the perfect example of breakthrough science developed at Hadassah by Profs. Benjamin
Reubinoffand Eyal Banin from the Hadassah Medical Center, that reached advanced stages of development following a successful technology
transfer. Hadasit will remain involved with CellCure through its collaboration and licensing agreement with the Company.”


 


HBL
- Hadasit Bio-Holdings Ltd. is a holding company with holdings in life sciences companies involved in medical and biotechnological
research and development. HBL was founded and listed on the Tel Aviv Stock Exchange to allow the public to have a share in the biotechnological
field. Most of
HBL portfolio companies originate in knowhow developed at the Hadassah Medical Center in Jerusalem.


 


“Centaurus
Investment Ltd (a BVI Company) is wholly owned by the trustees of a discretionary family trust, which is advised by CBG.


 


CBG,
chaired by Mr Vincent Tchenguiz, is a business group with diversified investment portfolio that includes structured financial
instruments and purchase, management and development of commercial and residential real estate properties. CBG is strategically focused
on the biotech industry but it is active also in renewable energy, infrastructures, cyber, enterprise software and digital media. To
date, CBG has participated in over $400 million of private equity, venture capital infrastructure and funds investment. CBG advises Centaurus
on its investments in Israel.


 


Hadasit
is the technology transfer company of the Hadassah Medical Center, established 100 years ago and considered one of Israel’s
major medical centers. The combination of practical experience, the ability to pinpoint medical needs and research at the forefront of
science has yielded a broad potential of ideas, innovation and developments in all aspects of medicine, including pharmaceuticals, diagnostics
and medical devices. Hadasit was founded in 1986 as a tool for commercializing medical technologies developed in the hospitals and invested
in turning ideas into existing products and services for the benefit of humanity. Hadasit cooperates with leading international companies
and research institutes as well as incubatorsand venture capital groups


 


CellCure
Neuroscience is a a biotechnological company focusing on developing cell therapy for degenerative retinal and macular diseases. CellCure’s
technology is based on human embryonic stem cells (hESC) which can be produced on a mass scale for any cell of the human body.


 


BioTime
is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what the company
believes to be the world’s premier collection of pluripotent cell assets. The foundation of BioTime’s core therapeutic technology
platform is pluripotent cells that are capable of becoming any of the cell types in the human body. Pluripotent cells have potential
application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative
conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based
on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader
applicability than pharmaceutical products. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics,
Inc. and OncoCyte Corporation, which BioTime founded and which, until recently, were majority-owned consolidated subsidiaries of BioTime.
BioTime also has a significant ownership interest in HBL at 14%.


 


SOURCE
Hadasit Bio-Holdings (HBL) and BioTime, Inc.


 


Contact
for media: Baruch Halpert, +44-7553-887187, bhalpert@sapircapital.com


 


©
Copyright BioTime, Inc.


 




    	-52-